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1. Introduction 
1.1 Background 
Dental implants and implant-supported restorations are a predictable alternative to 
removable partial dentures and fixed tooth-supported prostheses. Dental implants are 
commonly used to replace missing teeth, with 4.5 million implants placed annually 
worldwide. The success rate of implant therapy is greater than 90% after the first year in 
function [1].  
 
Bacterial biofilms colonize dental implants upon exposure to the oral cavity [2]. 
Undisrupted biofilms cause inflammation of the implant-mucosa unit, a process known as 
peri-implant mucositis. Peri-implant mucositis is defined as a reversible inflammatory 
condition of the mucosa without accompanying bone loss [3]. Evidence from animal 
studies suggests that persistent peri-implant mucositis may progress to peri-implantitis 
[4,5], which involves progressive bone loss. Loss of the affected implant may occur in 
patients with peri-implantitis. According to a recent review, 80% of patients and 50% of 
implants are affected with peri-implant mucositis whereas 28% of patients and 12% of 
implants are affected with peri-implantitis [6]. A more comprehensive understanding of 
peri-implant mucositis and the development of preventive strategies are needed. 
 
The biology of peri-implant mucositis is not well understood. Several human and animal 
studies have demonstrated that bacterial plaque accumulation produces similar clinical 
responses, such as erythema, bleeding on probing and increased gingival crevicular fluid 
(GCF) flow, in the tissues surrounding teeth and implants [7-9]. However, differences in 
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the quality and quantity of the inflammatory infiltrate [8] and the quality of the microbial 
flora [10] between gingiva and peri-implant mucosa have been reported. For example, a 
study by Nowzari et al. [11] found that cytokines associated with the innate immune 
response (e.g., IL-8, TNF-alpha) are exaggerated in the peri-implant mucosa in 
comparison to the gingiva [11]. Thus several neutrophil (PMN) activation markers, 
including myeloperoxidase and lactoferrin, have been proposed as potential risk markers 
for peri-implant disease [12]. In addition, although the microbiota of peri-implant and 
periodontal infections is for the most part similar [13], implant sites have been shown to 
harbor organisms not traditionally associated with periodontitis, such as staphylococci 
and enterics [14,15]. To date, the temporal microbial succession and resultant host 
response in the peri-implant mucosa versus the periodontium, in response to plaque 
accumulation, has not been characterized.  
 
1.2 Gingivitis 
1.2.1 Microbiota changes in gingivitis 
Gingivitis is defined by the presence of gingival inflammation without the loss of 
connective tissue attachment [16]. The etiology of gingivitis is bacterial plaque. A human 
experimental gingivitis model showed a significant shift in the bacterial biofilm 
composition from health to disease [17]. In this model, the microflora of healthy gingival 
sites was comprised of mainly aerobic Gram-positive cocci and rods. Two to four days 
after oral hygiene withdrawal, fusobacteria and filamentous bacteria proliferate. After 
four to nine days, the bacterial flora was characterized by the presence of curved rods and 
spirochetes. Gingivitis appeared 10 to 21 days following oral hygiene withdrawal and 
 3 
was reversible with reinstitution of oral care procedures at both the clinical and 
microbiological levels. The range in the timing of the development of clinical gingivitis 
among subjects was thought to be the result of variability in the individual host response 
to bacterial plaque [17,18]. No study, however, has ultimately resolved the genetic, 
microbiological or immunological parameters underlying susceptibility to gingival 
inflammation. 
 
Analyses of the subgingival microbiota in periodontal health and established gingivitis 
have shown differences in species predominance. Actinomyces naeslundii, 
Campylobacter gracilis, Prevotella nigrescens and Tannerella forsythia are increased in 
gingivitis samples. Health-associated species include Streptococcus oralis, Streptococcus 
gordonii, A. naeslundii and Actinomyces gerencseriae [19,20]. A three-year prospective 
study demonstrated elevated counts of A. naeslundii, Capnocytophagia gingivalis and 
Prevotella intermedia during baseline gingivitis and significant reductions in these 
species after one, two and three years of participation in a periodontal prevention regimen 
[21].  
 
The above-cited studies have used techniques to characterize the microflora such as 
cultivation and microscopic observation [18] or DNA-DNA hybridization [21]. A more 
recent study used high-throughput 16S rRNA pyrosequencing to investigate the changes 
in the microbiome development during experimental gingivitis, comprehensively 
characterizing the bacterial communities in plaque during the health to gingivitis 
transition [22]. Analyses were carried out at baseline and after one and two weeks of 
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interrupted plaque control. Pyrosequencing yielded 344,267 sequences that were 
clustered into an average of 299 species-level Operational Taxonomic Units (OTUs) per 
sample. There was no significant difference in richness between baseline and the end of 
experimental gingivitis induction (week 2). There was a significant difference in diversity 
across time points, with diversity significantly higher in two-week communities 
compared to both baseline and one-week communities. The significant increase in 
community diversity after two weeks of experimental gingivitis in the absence of 
increased richness indicates that increased diversity was due to increasing evenness. 
Therefore, the dominant species in health decreased in relative abundance over time 
while previously minor constituent species increased in relative abundance, resulting in a 
more even distribution of species after two weeks of plaque accumulation. Comparison of 
bacterial community structure of plaque samples using Principal Coordinate Analysis 
(PCoA) showed spatial separation of one- and two-week communities from baseline 
communities. The relative abundance of Actinobacteria was significantly higher at 
baseline compared to one and two weeks while Bacteroidetes were significantly higher in 
one- and two-week samples compared to baseline. However, there was considerable 
variability among subjects regarding the shifts in phyla during experimental gingivitis. In 
addition, the OTUs identified as Lautropia sp. HOTA94, Lachnospiraceae sp. HOT100, 
Prevotella oulorum and Fusobacterium nucleatum subsp. polymorphum were most 
significantly positively correlated with bleeding on probing (BOP). An OTU identified as 
Rothia dentocariosa was most significantly negatively correlated with BOP. The results 
of this study demonstrate that in the absence of oral hygiene, the transition from 
periodontal health to gingivitis is accompanied by a shift in the bacterial community 
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structure of plaque and an increase in bacterial diversity. The OTUs that increased in 
relative abundance as gingivitis developed were often obligate anaerobes and mostly 
gram-negative taxa of the genera Campylobacter, Fusobacterium, Lautropia, 
Leptotrichia, Porphyromonas, Selenomonas and Tannerella. These findings are in 
accordance with the observations of Loe and coworkers (1966), who reported an increase 
in the proportion of gram-negative cocci and rods as well as filaments, spirilla and 
spirochetes as gingivitis developed [18]. In the classic experimental gingivitis model, 
however, subjects abstained from oral hygiene for 21 days and gingivitis did not appear 
for 21 days in some subjects. The pyrosequencing study described above involved 
cessation of oral hygiene practices for only 14 days. This may have resulted in the 
inclusion of healthy sites among gingivitis data, when analyzing data according to time 
points, which is a significant limitation. There was also great variability at the phylum- 
and species-level among the subjects at baseline as indicated by the PCoA plots, which 
may compromise the ability to observe statistically significant changes in community 
structure from baseline to the gingivitis time points with a limited sample size. 
 
A study by Huang et al. (2014) examined the structure of the plaque microbiota in an 
experimental gingivitis model using pyrosequencing of the 16S rRNA gene in 50 subjects 
and developed a model to predict gingivitis severity and susceptibility based on plaque 
microbial structure. Five genera (e.g., Streptococcus) had elevated abundance at baseline 
whereas different 22 genera (e.g., Leptotrichia) had elevated abundance in both native 
and experimental gingivitis. All 150 species associated with health and gingivitis were 
clustered via PCoA based on relative abundance. The healthy and diseased taxa were 
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distinguished by a boundary separating baseline (healthy) samples from both native and 
experimental gingivitis, suggesting that microbiota structure is related to health or disease 
states. Native and experimental gingivitis microbial communities were largely consistent 
with respect to this boundary in the same subject. Therefore, community changes 
associated with gingivitis seem to recur similarly within subjects and each individual may 
have a personalized disease-associated configuration of the microbiota [23]. 
 
Huang et al. (2014) also observed that the projected coordinate of a given microbiota on 
the first principal component (PC1) of their PCoA plots demonstrated a gradient-like 
development of microbiota structure during experimental gingivitis and resolution, as 
changes in PC1 were consistent with the structural segregation between healthy and 
diseased microbiota. Thus, PC1 was used as a proxy for quantitatively measuring the 
development of the microbiota during the transition from native gingivitis to health and 
health to experimental gingivitis. The authors discovered that 15 genera were the drivers 
of heterogeneity among the microbiota along PC1. In health, genera traditionally 
associated with periodontitis (e.g., Fusobacterium, Tannerella, Treponema) were present 
in low abundance whereas their abundance increased along the PC1 axis. On the other 
hand, genera associated with health (e.g., Rothia, Haemophilus) were present in low 
abundance in the gingivitis samples and higher abundance in the healthy samples [23]. 
Additionally, gingivitis severity was correlated with PC1 values throughout the 
experimental gingivitis and resolution phases. Two distinct types of hosts emerged, with 
type I patients exhibiting less gingivitis sensitivity than type II patients. Type II patients 
demonstrated dramatic changes in PC1/microbial structure and gingivitis severity 
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compared to type I patients, who did not demonstrate such acute changes. For the average 
type II host, the rates of change in PC1 and gingivitis severity were 2.21-fold and 1.89-
fold higher than in an average type I host. Genera including Abiotrophia, Selenomonas 
and uncultured Lachnospiraceae were enriched in type II hosts compared with type I 
hosts. Interestingly, compared with type I hosts, those genera associated with type II 
hosts during native and experimental gingivitis were also higher in relative abundance in 
type II hosts at baseline. The authors concluded that heterogeneity of plaque microbiota 
among hosts may explain phenotypic variations of gingivitis sensitivity [23].  
 
Lastly, to determine whether PC1 could model disease progression and classify patients 
based on disease state, 41 additional subjects were sampled during native gingivitis and 
baseline for model validation. A microbial index of gingivitis (MiG) was derived based 
on the relative abundance of the 27 bacterial markers that distinguished health from 
native and experimental gingivitis. The predictive power of MiG27 was tested by 
determining the gingivitis statuses of the hosts using their native gingivitis microbiota. 
The accuracy of classification for a diseased versus healthy state was 94%. Therefore, 
plaque microbial structure is able to classify gingivitis susceptibility and severity in 
humans and the plaque microbial population during native gingivitis can predict the 
population structure during a later episode of experimentally-induced gingivitis in the 
same subject [23]. 
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In summary, gingivitis is associated with a shift in the microbiome consisting of 
increased gram-negative anaerobes as well as increased diversity. Plaque microbial 
structure may predict susceptibility to gingivitis.  
 
1.2.2 Host response in gingivitis 
The host immune system responds dramatically to the increased bacterial burden and the 
shift in community structure as plaque accumulates. The inflammatory process in patients 
with gingivitis is characterized by a cellular infiltrate composed of PMNs, B- and T-
lymphocytes, plasma cells, monocytes and macrophages [24,25].  
 
The histopathology of gingivitis is characterized by four stages. The evidence for these 
stages described by Page and Schroeder [26] was based on prevailing information from 
animal biopsies and some human adolescent samples. The initial lesion forms within 2 to 
4 days of plaque accumulation and involves vasculitis, increased GCF flow and migration 
of PMNs into the junctional epithelium. Loss of both epithelial cells in the coronal aspect 
of the junctional epithelium and perivascular collagen occurs. After 4 to 7 days, the early 
lesion forms. This stage in the evolution of gingivitis includes an accumulation of 
lymphocytes adjacent to the junctional epithelium and further loss of collagen. PMNs and 
lymphocytes are the predominant leukocytes in the infiltrate at this stage of gingivitis. 
The established lesion is the third stage of gingival inflammation. The distinguishing 
feature of this lesion is the predominance of plasma cells. Apical migration of the 
junctional epithelium and loss of connective tissue matrix elements are present. 
According to Page and Schroeder, the established lesion occurs after 7 days of plaque 
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accumulation. However, gingival biopsies from Brecx et al. [27] demonstrate that the 
lesion throughout 21-day abstention from oral hygiene during experimental gingivitis 
represents that of an early lesion, with numerous PMNs and lymphocytes but low 
numbers of plasma cells. Therefore, it may take longer than three weeks for the 
established lesion to develop. The established lesion may remain stable for a long period 
of time or progress to the advanced lesion, which is irreversible, involving pocket 
formation and bone loss [26].  
 
The interleukin 1 (IL-1) family of cytokines, interleukin 6 (IL-6), tumor necrosis factor 
alpha (TNF-alpha) and PGE2 are the cytokines and inflammatory mediators most 
consistently associated with gingivitis and periodontitis [28]. IL-1 alpha and beta are pro-
inflammatory cytokines that stimulate PGE2 release from monocytes and fibroblasts. 
PGE2 then induces osteoclastic bone resorption and matrix metalloproteinase (MMP) 
secretion. IL-1 beta also enables ingress of inflammatory cells into sites of infection, 
promotes bone resorption and stimulates release of MMPs that degrade proteins of the 
extracellular matrix. IL-1 beta is a principal mediator of the gingival inflammatory 
response and is produced primarily by macrophages and PMNs. IL-6 stimulates plasma 
cell proliferation and thus antibody production. IL-6 is produced by lymphocytes, 
monocytes and fibroblasts. TNF-alpha shares many properties with IL-1. It is pro-
inflammatory and stimulates MMP action, PGE2 production and bone resorption. It is 
secreted by monocytes and fibroblasts [28].  
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To determine the sequence of cytokine and lipid mediator activation within the 
periodontium during experimental gingivitis, Heasman et al. [29] collected GCF from 
healthy patients at baseline and weekly during four weeks of cessation of oral hygiene 
measures. GCF samples were assayed for several mediators, including PGE2, IL-1 beta 
and TNF-alpha. PGE-2 levels remained stable at baseline levels for the first three weeks 
and then increased by 2.5-fold at four weeks. IL-1 beta levels increased significantly at 
one week and remained at this heightened level for the duration of the study. These data 
suggest IL-1 beta is involved in the earliest phases of gingivitis whereas PGE2 is 
mediating the late response. TNF-alpha levels remained undetectable throughout this 
study. In another study of native gingivitis, however, both IL-1 beta and TNF-alpha 
levels in GCF were significantly higher in gingivitis subjects compared to periodontally 
healthy patients [30].   
 
The application of suspension bead multiplexing methods for the simultaneous analysis 
of multiple inflammatory mediators has been used to characterize the levels of 
inflammatory mediators associated with naturally occurring as well as experimental 
gingivitis in humans [31, 32]. These studies have shown that chronic gingivitis is 
associated with a 1.35-fold increase in IL-1 beta and a 2.1-fold increase in IL-6 in GCF 
[31]. Gingivitis induction during an experimental gingivitis model was associated with a 
2.6-fold increase in IL-1 beta and a 3.1-fold increase in IL-1 alpha. Interestingly, IL-8 
decreased significantly in GCF during gingivitis induction and rebounded to baseline 
during resolution [32]. 
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A study by Trombelli et al. [33] also evaluated IL-1 beta levels in GCF in naturally 
occurring as well as experimentally induced plaque-associated gingivitis. Experimental 
gingivitis was induced in one test quadrant while oral hygiene was continued in the 
contralateral control quadrant. In experimental gingivitis, IL-1 beta levels were 
significantly higher in test compared with control quadrants. Similar to the previously 
mentioned studies, GCF IL-1 beta was significantly higher in experimentally induced 
gingivitis sites compared to naturally occurring gingivitis sites. Higher IL-1 beta 
concentrations observed in experimentally induced gingivitis may reflect the increased 
microbial challenge to the gingival tissues associated with the experimental conditions of 
plaque accumulation.  
 
Other inflammatory mediators, such as IL-1 receptor antagonist (IL-1 ra), chemokine (C-
C motif) ligand 22 (CCL22) and growth-related oncogene (GRO), have been evaluated as 
potential markers for periodontitis, but not gingivitis. IL-1 ra is significantly increased in 
GCF from periodontitis patients compared to healthy controls, however this increased 
secretion of IL-1 ra in periodontitis does not inhibit IL-1 beta release [34]. CCL22, 
previously macrophage-derived chemokine, targets dendritic cells, NK cells and T cell 
subsets. CCL22 is a potent attractant for Th2 cells [35]. Gingival biopsies from 
periodontitis patients have greater CCL22 expression than biopsies from healthy patients 
[36]. GRO, a PMN chemoattractant, is significantly increased in GCF from periodontitis 
patients compared to healthy controls. However, no study has examined IL-1 ra, CCL22 
and GRO in gingivitis. 
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Overall, gingivitis involves inflammation of the gingival unit, without accompanying 
bone destruction, as a result of the presence of pathogenic bacteria leading to increased 
levels of inflammatory cytokines and tissue-destructive molecules.  
 
1.3 Peri-implant mucositis 
1.3.1 Microbiota changes in peri-implant mucositis 
The microbiota of periodontal and peri-implant infections are largely similar. Implants 
with clinical signs of peri-implantitis are associated with high counts and proportions of 
gram-negative anaerobic bacteria. Diseased implant sites have demonstrated a high 
prevalence of periodontal pathogens, including Porphyromonas gingivalis, Treponema 
denticola, T. forsythia, Fusobacterium species, P. intermedia and Aggregatibacter 
actinomycetemcomitans. However, some species not traditionally found in periodontitis 
sites have been isolated at implant sites. Staphylococcus aureus, enteric rods and Candida 
albicans have been isolated from sites with peri-implant disease [13]. 
 
Recently, pyrosequencing has been applied to the study of healthy and diseased peri-
implant microbiomes. In a study by Kumar et al. [37], subgingival and submucosal 
plaque samples were collected from a total of 40 patients with periodontitis (n = 10), peri-
implantitis (n=10) and periodontal (n = 10) and peri-implant (n = 10) health and analyzed 
using 16S pyrosequencing. Peri-implant sites demonstrated lower bacterial diversity than 
both healthy and diseased subgingival sites. The predominant phylotypes in both healthy 
and diseased peri-implant communities were members of the genera Butyrivibrio, 
Campylobacter, Eubacterium, Prevotella, Selenomas, Streptococcus, Actinomyces, 
 13 
Leptotrichia, Propionibacterium, Peptococcus, Lactococcus and Treponema. Lower 
levels of Prevotella and Leptotrichia and higher levels of Actinomyces, Peptococcus, 
Campylobacter, Streptococcus and Butyrivibrio were associated with diseased implants 
compared to healthy implants. Peri-implant disease communities also demonstrated lower 
levels of Prevotella, non-mutans Streptococcus, Lactobacillus, Selenomonas, 
Leptotrichia, Actinomyces and higher levels of Peptococcus, Mycoplasma, Eubacterium, 
Campylobacter, Butyrivibrio, Streptococcus mutans and Treponema than biofilms 
associated with periodontitis. Therefore, it appears that discrepancies are present in the 
phylotypes that colonize implant surfaces compared to teeth and different phylotypes are 
implicated in native peri-implantitis versus periodontitis. 
 
The majority of the limited research about the microbiota associated with peri-implant 
infection is related to peri-implantitis rather than peri-implant mucositis. Since peri-
mucositis is a precursor to the establishment of peri-implantitis, it is imperative to 
elucidate the microbial profile present during this transitional step in the progression to 
implant bone loss. In a combined experimental gingivitis and mucositis study by Salvi et 
al. (2012), clinical, microbiological and host inflammatory markers were monitored 
around teeth and implants. Fifteen subjects with healthy, restored implants underwent 
three weeks of undisturbed plaque accumulation followed by three weeks of optimal 
plaque control. The presence or absence of plaque deposits and gingival/mucosal 
conditions were evaluated weekly. Microbial samples were analyzed using DNA-DNA 
hybridization for 40 species. No differences in the total microbial DNA counts or 
detection frequency for putative periodontal pathogens were found between implant and 
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tooth sites at any time point. However, this study also did not find significant intra-
subject changes in levels of specific microorganisms during the experimental period for 
both implants and teeth [38]. In this design, sites were samples repeatedly over time, 
potentially disturbing the biofilm and preventing recolonization, which may explain the 
lack of difference between the groups. It should be noted that these results conflict with 
previously mentioned studies that found variations in the microflora around implants and 
teeth using different techniques. 
 
In a split-mouth design study [39], the bacterial communities at implant and tooth sites 
with native peri-implant mucositis or gingivitis, respectively, were compared via broad-
range PCR followed by DNA fingerprinting and sequencing of plaque samples. This 
technique does not provide information on abundance of taxa and is less comprehensive 
than high-throughput sequencing, which is a limitation of this study. Samples from the 
gingival sulci demonstrated significantly higher diversity than peri-implant samples. 
Twelve bacterial genera, including Campylobacter and Neisseria, were not found at 
implant sites but were frequently isolated at dental sites. In contrast, members of TM7 
were detected solely at implant sites. Although the findings of the previously discussed 
study oppose the findings of this study in terms of presence or absence of Campylobacter 
at implant sites, the two studies are in agreement with respect to peri-implant microbial 
diversity. The diversity of the microflora in sites demonstrating established peri-
implantitis or peri-implant mucositis seems reduced in comparison to that of periodontitis 
or gingivitis [39]. Different microbiomes surrounding implants and teeth may thus affect 
the mechanisms by which initial inflammatory lesions progress to irreversible changes. 
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1.3.2 Host response in peri-implant mucositis 
It has been proposed that peri-implant soft tissues may develop a stronger inflammatory 
response to plaque accumulation than soft tissues around teeth. Biopsies harvested from 
one tooth and one implant site in partially edentulous patients in health and after three 
weeks of undisturbed plaque accumulation demonstrated a trend toward significantly 
increased B and T cells in the peri-implant mucosa compared to the gingiva [8]. Similar 
evidence was found in the Salvi et al. (2012) study. Weekly GCF samples were analyzed 
for matrix metalloproteinase-8 (MMP-8) and IL-1ß levels. GCF levels of MMP-8, but not 
IL-1ß, were significantly higher at implants compared with teeth over the six-week 
experimental period. Three weeks after the reinstitution of oral hygiene, reversibility of 
experimental gingivitis and mucositis was achieved at the biomarker level. Clinically, 
gingival and peri-implant mucosal health were not achieved after three weeks of resumed 
plaque control, suggesting that longer healing periods are required for both teeth and 
implants [38].  
 
In addition to MMP-8, other indicators of PMN function, such as lactoferrin and elastase, 
have been identified as potential biomarkers for peri-implantitis. Lactoferrin, an iron-
binding protein stored in secondary neutrophilic granules that are released during PMN 
chemotaxis, is associated with the number of PMNs present in a lesion. Elastase, a serine 
protease stored in primary neutrophilic granules, is released extracellularly during 
phagocytosis and activation of PMNs and degrades collagen, laminin and fibronectin. In 
a study that aimed to characterize the inflammatory host response around implants and 
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teeth in patients with peri-implantitis, GCF samples were collected from implants with 
peri-implantitis, stable implants in patients with both stable and peri-implantitis implants 
and control implants in patients with stable implants only [12]. In patients with peri-
implantitis, lactoferrin concentration was higher at implants with peri-implantitis than at 
stable implants. Elastase activity was higher at implants with peri-implantitis compared to 
stable implants in controls. Therefore, lactoferrin concentration and elastase activity in 
crevicular fluid are markers of site-specific inflammation, specifically PMN activation, 
around dental implants. 
 
The neutrophilic enzyme myeloperoxidase (MPO) is a heme-containing enzyme with 
non-specific peroxidase activity, enabling oxidation of a wide range of substrates. In the 
presence of hydrogen peroxide and chloride ions, MPO catalyzes the oxidation of Cl- into 
hypochlorous acid, which kills many bacterial and fungal species in vitro. It has been 
demonstrated that total amounts of MPO are significantly higher in the peri-implant 
sulcular fluid surrounding implants with peri-implantitis or peri-implant mucositis 
compared to that of healthy implants. Also, MPO activity increases with increasing 
pocket probing depth (PPD), gingival index (GI) and bleeding on probing (BOP) scores. 
Therefore, MPO could be an important marker for peri-implant mucositis and peri-
implantitis [40].  
 
Since little is known about the host response during peri-implant mucositis, the host 
responses around teeth and implants in health and during periodontitis/peri-implantitis 
may provide a foundation for understanding peri-implant mucositis. Implant sites 
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demonstrate higher concentrations of inflammatory cytokines such as IL-8 and TNF-
alpha [11]. A recent study compared the histology of periodontitis and peri-implantitis 
lesions in 40 patients with generalized severe chronic periodontitis and 40 patients with 
severe peri-implantitis. Peri-implantitis biopsies demonstrated significantly larger 
infiltrated connective tissue areas compared to periodontitis samples. In addition, peri-
implantitis lesions contained significantly larger area proportions and densities of 
CD138-, CD68- and MPO-positive cells than periodontitis lesions [41].  
 
In summary, the results of these studies demonstrate that there are dissimilarities in the 
host responses around implants evidenced as significant differences in histopathology and 
inflammatory markers measured in GCF. Most studies suggest an exacerbated response 
around implants in comparison to teeth.  
 
1.4 Rationale for this study 
Overall, the microbiome and host response associated with peri-implant mucositis are not 
fully understood. Although there are data suggesting that, compared to either 
periodontitis or gingivitis, peri-implant lesions demonstrate decreased microbial diversity, 
differences in the presence and prevalence of certain bacteria and an increased response 
from host inflammatory proteins, it is yet to be determined whether peri-implant 
mucositis processes closely mimic those of gingivitis. 
 
To the extent that peri-implant mucositis and gingivitis differ in associated microbiomes 
and/or host response, clinical approaches to diagnosis, prevention and therapy may also 
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differ. As the gateway lesion to peri-implantitis, peri-implant mucositis represents a 
critical step in avoiding implant failure. Therefore, understanding characteristics of the 
microflora in health and initial disease, as well as destructive host inflammatory and 
immune response to bacterial pathogens, can guide research and the management of 
implants. 
 
Most studies to date have examined peri-implantitis rather than its precursor, peri-implant 
mucositis. In the natural dentition, understanding the development of salient disease, 
periodontitis, derives from the characterization of its precursor, gingivitis. Similarly, our 
grasp of peri-implantitis must be based on a more detailed examination of peri-implant 
mucositis. The dramatic distinctions between implants and teeth, for example in 
molecular composition (titanium versus enamel), physical (especially surface and 
anatomical) qualities, histological attachment mechanisms, blood supply and mode of 
establishment in the mouth (eruption versus surgical insertion), raise the possibility that 
the bacterial species and communities associated with implants may have limited 
resemblance to those associated with teeth. These microbial differences, and such unique 
features as lack of periodontal ligament and reduced vascularity, could lead to variations 
in host response during initiation and progression of disease. 
 
The present study aims to further characterize the evolution of the whole microbial 
profile and the associated changes in host response at teeth and implant sites in three 
phases: during a native condition, a 21-day period of oral hygiene cessation and after 
resumption of oral hygiene practices. 
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1.5 Hypothesis 
For the above-mentioned reasons, we hypothesize that the microbial and immune 
responses differ between implants and teeth during native and experimental peri-implant 
mucositis/gingivitis and after peri-implant mucositis/gingivitis resolution. 
 
2. Objectives 
2.1. Specific aims 
 Aim 1. To cross-sectionally compare the microbial biofilms and GCF 
inflammatory markers between teeth and dental implants in their native state 
 Aim 2. To longitudinally evaluate the changes in the microbial flora and GCF 
inflammatory markers during 21 days of de novo plaque accumulation around dental 
implants in comparison to teeth 
Aim 3. To compare the immunological and microbiological responses after oral 
hygiene measures are resumed around dental implants and teeth 
 
3. Study design and methods 
This is a controlled clinical trial to compare the responses to de novo plaque 
accumulation in peri-implant soft tissue and gingiva within subjects (n=15). We 
evaluated immunological and microbiological parameters at a baseline native state, over 
21 days of experimental peri-implant mucositis/gingivitis and following reinstitution of 
oral hygiene practices. To achieve the previously mentioned objectives, we collected 
GCF and biofilm samples from two Straumann implants and two natural teeth in 
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systemically healthy patients. Host inflammatory markers were analyzed via ELISA and 
Luminex technology. The microbiome composition of the plaque samples was 
determined by high-throughput sequencing of the bacterial 16S rRNA gene. 
 
3.1 Study population 
Eighteen voluntary participants were recruited among the patient population formerly 
treated with implant therapy at the University of Connecticut, School of Dental Medicine. 
Table 1 shows the inclusion and exclusion criteria for this study. 
 
Table 1. Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
• ≥21 years of age; 
• Presence of 2 implants in the maxillary or 
mandibular arch supporting fixed 
restorations in function for at least 1 year 
(Test);  
• Presence of 2 teeth in the corresponding 
position of the implant (Control);  
• Absence of active infections at both test and 
control sites 
• Absence of radiographic bone loss at both 
test and control sites 
• Pocket depth ≤4mm at both test and control 
sites 
• Must give written informed consent. 
 
• Treatment with antibiotics for any dental or 
medical condition within 1 month before 
screening;  
• Systemic diseases that require chronic use 
of anti-inflammatory medications, 
antibiotics or anticoagulants;  
• Ongoing medications for systemic 
conditions initiated <3 months before the 
start of the study or the requirement to take 
prophylactic antibiotics for invasive dental 
procedures; 
•  Significant organ disease including 
impaired kidney function, heart murmur, 
rheumatic fever, bleeding disorder;  
• Active infectious diseases such as hepatitis, 
tuberculosis and HIV;   
• Clinically detectable caries and/or 
periodontal disease;  
• Tobacco use of any kind;  
• Use of medications affecting periodontal 
status (diphenylhydantoin, cyclosporine, 
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etc.) 
• No pregnancy or lactation or expectation to 
become pregnant within next 3 months. 
 
3.2 Clinical study design 
This is a controlled cross-arch study. The test site included two Straumann Tissue Level 
implants supporting fixed restorations in function for at least one year. The control site 
included two teeth in the corresponding position of the implants. Subjects were seen at a 
screening visit and at a “pre-experimental phase” visit to collect information on naturally 
occurring gingivitis and peri-implant mucositis if present. After prophylaxis to achieve 
optimal gingival and mucosal health, a customized stent was given to subjects to wear 
during toothbrushing and flossing on test and control sites to prevent daily plaque 
removal from these areas. Oral hygiene procedures were resumed after 21 days of plaque 
accumulation. Clinical parameters were measured and saliva, GCF and biofilm samples 
were obtained weekly for the duration of the study (Figure 1). 
 
 22 
Figure 1. Experimental design and procedures. GI, modified plaque index (PlI) and 
angulated bleeding score (ABS) were recorded. GCF samples were collected for GCF 
flow determination and host marker evaluations. Microbial sampling was also performed 
Blood and saliva samples were stored at -80°C for future analysis. 
 
3.3 Clinical study procedures and sample collection 
3.3.1 Informed consent 
During the screening visit, the experimental procedure was explained and a written 
informed consent was presented to the patient. Inclusion and exclusion criteria were 
verified.  
 
3.3.2 Vitamin C administration 
To prevent subclinical vitamin C deficiency that could affect susceptibility to 
inflammation, eligible subjects received a supply of vitamin C supplement (250 mg/day) 
to take for the 56-day pre-trial and trial period.  
 
3.3.3 GCF flow rate 
For determination of GCF flow rate, GCF was collected for 5 seconds from the mesial 
and buccal surfaces of the most posterior teeth and implants and measured according to 
Periotron 8,000 manufacturer’s instructions (OraFlow Inc., Plainview, NY, USA). 
Following isolation of the site with cotton rolls, a Periopaper strip was inserted 1-2 mm 
subgingivally into the gingival sulcus.  
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3.3.4 Collection of GCF for host marker evaluation 
GCF was also collected for host marker evaluation. GCF was collected for 30 seconds 
from the mesial and buccal surfaces of the most anterior teeth and implants. Samples 
were placed on ice, transported to the lab and stored at -80°C.  
 
3.3.5 Clinical exam 
GI was recorded on the mesial and buccal surfaces of teeth and implants using the Silness 
and Löe (1964) [42] method without the bleeding component, according to the 
modification described by Trombelli et al. (2004) [43]. Plaque Index (PlI) on mesial and 
buccal surfaces of teeth and implants was measured using the Silness and Löe (1964)[67] 
method and recorded according to Furuichi et al. (1992)[44]. ABS, according to the 
modification of the score by van der Weijden et al. (1994)[45], was recorded on the 
mesial and buccal surfaces of teeth and implants.  
 
3.3.6 Biofilm collection 
Biofilm samples were collected at the distal surfaces of the most posterior implant and 
tooth for visits 1, 3, 5 and 7. For visit 4, plaque was collected from the distal surfaces of 
the most anterior implant and tooth. A plastic curette was inserted into the sulcus and the 
biofilm was removed by a single stroke. The sample was placed into a 50µl Tris-EDTA 
(TE) buffer solution, which was stored at -80°C until further microbiological analysis.  
 
3.3.7 Stent fabrication 
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An alginate impression was made for fabrication of the stent necessary to prevent 
disturbance of plaque accumulation during oral hygiene procedures.  
 
3.3.8 Oral hygiene and prophylaxis during visits 1 and 2 
Oral hygiene instruction (OHI) was provided to subjects. A toothbrush, floss and non-
fluoridated toothpaste were distributed to each participant and participants were 
instructed to abstain for mouth rinse use during the study. Patients also received full 
mouth scaling and polishing during visit 1. If GI did not equal zero on visit 2, another 
session of scaling, polishing and OHI was provided prior to proceeding with the protocol. 
Lastly, patients were provided with the stent and instructed to wear it for 21 days during 
oral hygiene practices. 
 
3.3.9 Colgate Total® toothpaste administration and reinstitution of oral hygiene 
At the end of visit 6 (day +21), OHI was given and subjects returned the stent and 
reinstituted oral hygiene practices. Subjects were provided with Colgate Total® 
toothpaste to be used daily. In the final visit, subjects were given OHI and scaling and 
polishing were also provided. 
 
3.3.10 Exam and sample collection sequence 
During each visit, GI was recorded first. Second, GCF was collected for GCF flow rate 
determination and host marker evaluation. Paper strips contaminated with saliva and/or 
blood were discarded. Then biofilm samples were obtained. Following GCF and biofilm 
 25 
sample collection, ABS was measured. Lastly, plaque was stained with disclosing 
solution, if require, and PlI was recorded. 
 
3.4 Microbiological laboratory procedures  
DNA was isolated from individual plaque samples and quantified. Total microbial load 
was determined via quantitative real time PCR. Microbiome composition of the samples 
was determined via high-throughput sequencing of the 16S rRNA gene using the Illumina 
MiSeq platform [46].  
 
3.4.1 DNA isolation 
Plaque samples were collected and placed in 50 µl of TE buffer. Samples were re-
suspended in lysis buffer with lysozyme at 37°C for 30 minutes. Next, AL buffer and 
proteinase K (Qiagen DNA extraction kit) were added and the suspension was incubated 
at 56°C overnight. Samples were then incubated at 95°C for 5 minutes to inactivate 
proteinase K. DNA isolation was performed using a commercially available kit according 
to the instruction of the manufacturer (Qiagen DNeasy Blood and Tissue kit). DNA was 
eluted in 50 µl of MD5 solution (MoBio Laboratories) and its concentration was 
measured using a NanoDrop instrument (ThermoScientific). A positive control (180 µl of 
a known bacterial culture) was included to verify technique performance and a negative 
control (180 µl of lysis and TE buffers without any sample) was included for the 
assessment of sample contamination by foreign DNA. 
 
3.4.2 Subgingival bacterial load quantification by real time PCR 
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The determination of the subgingival bacterial load of plaque samples was performed via 
real-time PCR using a TaqMan probe (Table 2) and universal 16S rRNA primers (Table 3) 
[47]. Samples were analyzed in singlicate in 96-well plates with a CFX96 Real-time 
system C1000 Thermocycler (BioRad). Standard curves were generated using DNA from 
serial dilutions of a pure culture of F. nucleatum. 
Table 2. TaqMan probe [47]. 
(6-FAM)-5’-CGTATTACCGCGGCTGCTGGCAC-3’-(TAMRA) 
 
Table 3. Universal primers used to determine subgingival bacterial load [47]. 
Forward: 5’-TCCTACGGGAGGCAGCAGT-3’ 
Reverse: 5’-GGACTACCAGGGTATCTAATCCTGTT-3’ 
 
 
Each reaction was performed in a total volume of 50 µl containing 25µl TaqMan Master 
Mix, 5 µl of each forward and reverse primer, PCR water (9 µl for plaque samples; 5 µl 
for standard curve), and 1 µl plaque DNA sample or 5µl of diluted DNA from F. 
nucleatum for standard curves. The qPCR cycle consisted of 95°C for 10 minutes, 
followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. The 
quantification of subgingival bacterial load was calculated using qPCR software (CFX 
Manager, Bio-Rad) and F. nucleatum standard curve with known 16S rRNA copy 
number. 
 
3.4.3 Microbiome determination  
Amplicon libraries were prepared using fusion primers with adaptor, indices, spacer and 
primers. Tables 4-6 list fusion primers used for MiSeq sequencing. Figures 2 and 3 
provide schematic representations of the fusion primers and sequencing strategy, 
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respectively. These primers amplify a 423 bp region of the 16S rRNA gene spanning V1 
and V2, the hypervariable regions that perform best in the assignment of species 
taxonomy to short sequence reads [48].  
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Table 4. Forward and reverse adaptor sequences used in fusion MiSeq primers. 
 
 
 
Table 5. Sequences of universal primers used in fusion MiSeq primers. 
  
 
 
 
 
Table 6. Forward indices used    Table 7. Reverse indices used  
in MiSeq primers.     in Miseq primers.  
  
  
  
 
  
  
  
 
 
 
 
 
 
 
 
 
 
Forward and reverse adaptor sequences  
5’-CAAGCAGAAGACGGCATACGAGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3’ 
5’- AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT-3’ 
Universal primers  
Forward 5’-AGAGTTTGATCMTGGCTGAC-3’ 
Reverse 5’-CYIACTGCTGCCTCCCGTAG-3’ 
Forward indices 
GTGGTATGGGAG 
ACTTTAAGGGTG 
GAGCAACATCCT 
TGTTGCGTTTCT 
ATGTCCGACCAA 
AGGTACGCAATT 
ACAGCCACCCAT 
TGTCTCGCAAGC 
GAGGAGTAAAGC 
GTTACGTGGTTG 
TACCGCCTCGGA 
CGTAAGATGCCT 
TACCGGCTTGCA 
ATCTAGTGGCAA 
CCAGGGACTTCT 
CACCTTACCTTA 
ATAGTTAGGGCT 
GCACTTCATTTC 
Reverse indices 
TGCAGATCCAAC 
CCATCACATAGG 
GTGGTATGGGAG 
ACTTTAAGGGTG 
ATGTCCGACCAA 
AGGTACGCAATT 
ACAGCCACCCAT 
TGTCTCGCAAGC 
GAGGAGTAAAGC 
GTTACGTGGTTG 
TACCGCCTCGGA 
CGTAAGATGCCT 
TACCGGCTTGCA 
ATCTAGTGGCAA 
CCAGGGACTTCT 
CACCTTACCTTA 
ATAGTTAGGGCT 
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Figure 2. Fusion primers designed for bidirectional sequencing using the MiSeq Illumina 
platform. Primers included 5’ and 3’ adaptor sequences, index 1 and 2, heterogeneity 
spacers, forward and reverse 16S rRNA gene universal primers and bacterial template. 
Indices served to tag each sample, allowing for massive parallel sequencing. 
Heterogeneity spacers were 0 to 7 bp sequences implemented to introduce library 
diversity. 
 
 
 
Figure 3. Sequencing strategy. A 528 bp amplicon was generated and sequenced 
bidirectionally with the MiSeq Reagent Kit v3 (300 cycles). A 150 bp overlap was 
expected after assembling the forward and reverse reads. 
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PCR was performed in thin-walled tubes with a C1000 Touch Thermocycler (BioRad, 
Hercules, CA). Each reaction was performed in triplicate using a total volume of 20 µl 
containing 10.5 µl water, 1.2 µl forward primer, 1.2 µl reverse primer, 0.4 µl 10mM 
dNTPs, 0.6 µl 50mM MgSO4, 0.125 µl Platinum Taq polymerase and 2 µl 10X buffer. 
Thermal cycler conditions were as follows: pre-heating of samples at 95°C for 3 minutes 
followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing at 50°C for 30 
seconds, and elongation at 72°C for 60 seconds. This was followed by a final elongation 
step at 72°C for 9 minutes. Reaction products were evaluated by gel electrophoresis (1.5% 
agarose gel run at 100V for 20 minutes), DNA was stained using ethidium bromide and 
visualized under short-wavelength UV-light (Gel-Doc system, BioRad). The AmpureXP 
bead was used to purify PCR products and select fragments of a size greater than 300 bp. 
Finally, amplicon library quantification analysis was conducted using Qubit (Life 
Technologies) and bacterial amplicon libraries were sequenced with Illumina MiSeq V3 
chemistry (MiSeq Sequencer). For this, the sample library and 20% PhiX were denatured 
and loaded to the flow cell.  
 
3.4.4 Processing and analysis of bacterial sequences 
Sequences obtained from MiSeq were processed using the mothur software [49]. Forward 
and reverse sequence reads were trimmed using a sliding window strategy by quality 
score (Q30 > 35) and a window size of 50 bp. Forward and reverse reads were then 
assembled. Primers and indices were trimmed and sequences filtered to exclude 
sequences with ambiguous base calls and read lengths less than 200 bp and 400 bp. 
Unique sequences were aligned using the SILVA database as a reference [50] and ends 
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trimmed such that sequences only included a comparable anchor region. Sequences were 
further processed by a modification of the single linkage algorithm [51,53] to determine 
sequences with up to 2 bp difference from a more abundant sequence and merge their 
counts, which reduces variability thereby reducing errors caused by sequencing. Chimeric 
sequences were then removed by applying the UChime algorithm [53] as implemented in 
mothur. Next, a distance matrix was produced and sequences were clustered into OTUs 
based on a 3% difference [54]. Classification of sequences was performed using the 
Ribosome Database Project (RDP) classifier with the RDP reference trainset [55] or the 
Human Oral Microbiome Database (HOMD) trainset (www.homd.org) as templates. 
OTUs were classified according to the majority taxonomic assignments for reads in each 
OTU. If a taxonomic assignment at the species level was not possible, the most abundant 
sequence from each OTU was compared by Blast to the HOMD. In cases of more than 97% 
homology of the representative sequence to an HOMD reference sequence, the HOMD 
match was also included in parenthesis as part of the OTU taxonomy. 
 
Alpha diversity analysis comprised richness, evenness and total diversity. Richness was 
assessed by evaluation of the number of observed OTUs. Evenness was obtained using 
the Shannon evenness index. Total diversity was evaluated by the inverse of the Simpson 
Index and the non-parametric Shannon index [56-58]. Beta diversity was measured with 
the Theta YC distance [59] for comparison of communities based on structure. PCoA was 
performed in mothur and graphs were visualized using rgl application in R (http://www.r-
project.org). 
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3.5 Host inflammatory marker analysis 
GCF volume was measured with the Periotron 8000 (OraFlow Inc., Plainview, NY), as it 
has been shown to correlate with peri-implant and gingival inflammation [43]. The site 
was first isolated with cotton rolls to prevent contamination with saliva. Then a 
Periopaper strip was gently inserted 1-2 mm into the gingival sulcus by a calibrated 
examiner for 5 seconds for GCF volume measurement or 30 seconds for host marker 
evaluation. Samples contaminated with blood were discarded. Functional activation of 
PMNs was assessed by MPO and lactoferrin GCF levels as described below. MPO was 
assayed as representative of neutrophilic oxidative killing mechanisms. Lactoferrin was 
measured as representative of non-oxidative killing mechanisms. GCF levels of IL-1 
alpha, IL-1 beta, IL-1 ra, IL-8, TNF-alpha, CCL22 and GRO (alpha, beta and gamma) 
were quantified with a multiplex assay, allowing for simultaneous cytokine quantification 
(EMD Millipore, Billerica, MA). 
 
3.5.1 Lactoferrin and MPO quantification in GCF 
MPO and lactoferrin in GCF were quantified by enzyme-linked immunosorbent assay 
(ELISA). Elution buffer was prepared with 0.05% Tween 20, 1 mg/ml BSA in PBS with 
complete proteinase inhibitor (Roche Life Science, Indianapolis, IN) and filtered with 
0.22 µm pore size syringe filter. Each paper strip was eluted with 60 µl of elution buffer, 
vortexed and stored overnight at 4°C. Then samples were vortexed, briefly centrifuged so 
that all elution buffer remained in the bottom of the eppendorf tube and both the eluted 
paper strips and GCF samples were transferred to new eppendorf tubes separated by a 
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basket. Samples were then centrifuged at 13,000 rpm for 10 minutes. Eluted samples 
were then diluted. Optimal dilutions for lactoferrin and MPO were determined after pilot 
trials. 
 
Lactoferrin ELISA was performed with a commercially available kit according to the 
instructions of the manufacturer (Abcam, Cambridge, MA). Fifty µl of the GCF samples 
diluted by 1:500 were added to 96 wells that were precoated with a lactoferrin-specific 
antibody and incubated for two hours. Subsequently, a lactoferrin-specific biotinylated 
detection antibody was added, incubated for one hour and washed with wash buffer. 
Streptavidin-peroxidase conjugate was added, incubated for 30 minutes and unbound 
conjugates were washed away with wash buffer. Chromogen substrate was then used to 
visualize the streptavidin-peroxidase enzymatic reaction. This substrate produced a blue 
color product that changed to yellow after adding acidic stop solution. The absorbance 
was read on a microplate reader at a wavelength of 450 nm.  
 
A similar assay was completed for MPO quantification (R & D, Minneapolis, MN). An 
MPO-specific mouse monoclonal antibody was precoated on 96-well plates. Standards 
and test samples diluted by 1:2000 were added to the wells and incubated. The 
biotinylated detection MPO-specific goat polyclonal antibody was added followed by 
washing. Avidin-Biotin-Peroxidase Complex was added and incubated. Subsequently, 
TMB was used to visualize the enzymatic reaction and absorbance was read on a 
microplate reader. Target concentrations for MPO and lactoferrin were calculated with a 
four-parameter logistic equation using SOFTmax Pro software (Sunnyvale, CA). 
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3.5.2 IL-1 alpha, IL-1 beta, IL-1 ra, IL-8, TNF-alpha, GM-CSF, CCL22 and GRO 
quantification in GCF 
IL-1 alpha, IL-1 beta and IL-1 ra, IL-8, TNF-alpha, GM-CSF, CCL22 and GRO (alpha, 
beta and gamma) in GCF were analyzed by multiplex assay, allowing for simultaneous 
quantification of multiple cytokines (EMD Millipore). After a pilot trial, it was 
determined that IL-1 ra required a 1:10 dilution. Samples for other cytokines were not 
diluted. For multiplex cytokine detection, microspheres coated with fluorescent dyes and 
specific capture antibodies were added to the sample. After the bead captured an analyte 
from the test sample, a biotinylated detection antibody was introduced and the reaction 
mixture was incubated with streptavidin conjugate (reporter molecule) to complete the 
reaction on the surface of each microsphere. Samples were passed through a primary 
laser, exciting the dyes to mark the microsphere, and then passed through a secondary 
laser, exciting the fluorescent dye on the reporter molecule. High-speed digital-signal 
processors identified each microsphere and quantified the result of its bioassay based on 
the fluorescent reporter signals (Luminex 200). Target concentrations were calculated 
with a four-parameter logistic equation using SOFTmax Pro software (Sunnyvale, CA). 
 
3.6 Statistical analysis 
Clinical microbiological and host inflammatory marker assessments were performed 
across groups for Aims 1 and 3. For Aims 2 and 3, both within group and across group 
comparisons were performed. Statistical significance was considered when p values were 
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<0.05 and below the threshold determined by multiple testing using the Benjamini-
Hochberg false discovery rate method.  
 
Paired-sample Wilcoxon Signed-Rank tests were employed to assess differences in 
clinical parameters, host inflammatory markers, subgingival bacterial load, alpha 
diversity and OTU abundance. For comparisons of OTU relative abundance, only those 
OTUs with at least 0.1% relative abundance in at least one sample were considered (533 
OTUs). Significant separation of clusters after PCoA analysis was evaluated via analysis 
of molecular variance (AMOVA) [60]. Bivariate Spearman’s Rank-Order Correlation 
tests were used to evaluate correlation of clinical, host and microbiological variables in 
implant and teeth sites (between group correlations), to evaluate the correlation among all 
variables within a group (within group correlations) and to evaluate the correlation of 
OTU relative abundance with Principal Component 1 in PCoA plots.  
 
4. Results 
4.1 General considerations 
Clinical results were presented in a thesis by Dr. Jonah Barasz and have been updated for 
this thesis (Figure 4). Fifteen patients out of 18 enrolled completed the trial. One patient 
was excluded from the study when suppuration of the mucosal margin at a test site was 
observed at visit 5 (day 14). The site was treated with debridement, irrigation and 0.12% 
chlorhexidine rinse for seven days. The condition resolved completely after seven days. 
Two subjects exited the study due to changes in medical condition unrelated to the study 
proceedings prior to visit 1 (day -14) and visit 2 (day -7). Figures 5, 6, and 7 present 
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results of inflammatory mediator assays. GM-CSF was not included because it was non-
detectable in most samples. Subgingival bacterial load measurement via qPCR is shown 
in Figure 8. Microbiome sequencing yielded 11,167,919 sequences after preprocessing, 
with an average of 27,674 sequences per sample. The range of sequences per samples 
was 13 to 53,374, however. Since comparison among samples requires the same number 
of reads, samples were subsampled to contain 5,298 sequences. This excluded 13 samples 
from the analysis (visit 1 for subjects 11 (control), 14 (control and test) and 17 (control); 
visit 3 for subjects 2 (test), 4 (test), 14 (test), 17 (control and test) and 18 (control); visit 4 
for subject 7 (test); visit 7 for subjects 5 (test) and 16 (control)). 
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Figure 4. Clinical response of teeth and implants during the trial. Box plots show GCF 
volume (a), GI (b), PlI (c) and ABS (d) in test (implants) and control (teeth) sites during 
study visits. Within group comparisons are shown in tables below the graphs. Across and 
within group differences at each time point are indicated by asterisks. * = p<0.05; ** = 
p<0.01 
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Figure 5. Inflammatory response of teeth and implants during the trial. Box plots show 
lactoferrin (LF; a), MPO (b), IL-8 (c) and CCL22 (d) concentrations in test (implants) 
and control (teeth) sites during study visits. Within group comparisons are shown in 
tables below the graphs. Across and within group differences at each time point are 
indicated by asterisks. * = p<0.05  
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Figure 6. Inflammatory response of teeth and implants during the trial. Box plots show 
IL-1 alpha (a), IL-1 beta (b), IL-1 ra (c) and TNF-alpha (d) concentrations in test 
(implants) and control (teeth) sites during study visits. Within group comparisons are 
shown in tables below the graphs. Across and within group differences at each time point 
are indicated by asterisks. * = p<0.05; ** = p<0.01 
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Figure 7. Inflammatory response of teeth and implants during the trial. Box plot shows 
GRO concentration test (implants) and control (teeth) sites during study visits. Within 
group comparisons are shown in tables below the graph. * = p<0.05 
 
 
 
Figure 8. Microbiological response of teeth and implants during the trial. Box plot shows 
subgingival bacterial load in test (implants) and control (teeth) sites during study visits. 
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Within group comparisons are shown in table below the graph. Across and within group 
differences at each time point are indicated by asterisks. * = p<0.05; ** = p<0.01 
 
 
Figure 9. Microbiological response of teeth and implants during the trial. Box plots 
shows alpha diversity, as measured by richness (a), evenness (b), non-parametric 
Shannon Index (c) and Inverse Simpson Index (d), in test (implants) and control (teeth) 
sites during study visits. Within group comparisons are shown in tables below the graphs. 
Across and within group differences at each time point are indicated by asterisks. * = 
p<0.05; ** = p<0.01 
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4.2 Results related to Aim 1 
The first aim of this thesis (Aim 1) was to cross-sectionally compare the microbial 
biofilms and GCF inflammatory markers between teeth and implants at the baseline visit 
(day -14), assuming this visit represents the native state ranging from health to gingivitis 
or peri-implant mucositis. 
 
4.2.1 Clinical results 
On day -14, GI was significantly higher at teeth compared to implants (Figure 4b). There 
were no significant differences in GCF volume, PlI or ABS, however (Figure 4a, c, d).  
 
4.2.2 GCF inflammatory marker results 
Although GI, a marker for clinical inflammation, was higher in teeth than implants on 
day -14 and ABS, GCF volume and PlI did not differ between groups, implants 
demonstrated significantly higher concentrations of lactoferrin (Figure 5a), IL-1 ra 
(Figure 6c) and TNF-alpha (Figure 6d) compared to teeth. There was also a trend for 
higher MPO (Figure 5b), CCL22 (Figure 5d), IL-1 alpha (Figure 6a), IL-1 beta (Figure 
6b), IL-8 (Figure 5c) and GRO (Figure 7) concentration at implants compared to teeth at 
this time point. These results suggest that implants demonstrate higher inflammation at 
the molecular, but not clinical, level than teeth during the native state. 
 
4.2.3 Microbiological results 
There were no significant differences in subgingival bacterial load (Figure 8) or alpha 
diversity, as measured by richness (Figure 9a), evenness (Figure 9b), non-parametric 
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Shannon Index (Figure 9c) and Inverse Simpson Index (Figure 9d) between implants and 
teeth. Although implants and teeth had equal microbial load, as measured by PlI and 16S 
rRNA copy number, and teeth had increased clinical inflammation, as measured by GI, 
implants demonstrated higher concentrations of pro-inflammatory cytokines than teeth 
during the native state.  
 
On day -14, PCoA of distance among samples based on an ecology metric that takes into 
account OTU presence and proportions (Theta YC) revealed no differences between teeth 
and implants on day -14, suggesting that community structure in teeth and implants is the 
same in the native condition (Figure 10).  
 
Figure 10. PCoA plot of community structure (Theta YC) in teeth and implants on day -
14. Gray = teeth; black = implants. 
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Prior to adjusting for multiple comparisons, the relative abundances of 
Propionibacterium propionicum (p<0.05), C. gracilis (p<0.05), Capnocytophaga sp. 
(HOT336; p<0.05), Selenomonas sputigena (p<0.05) and A. gerencseriae (p<0.05) were 
significantly greater in teeth than implants (Figure 11). On the other hand, 
Pasteurellaceae sp. (Terrahaemophilus aromaticivorans HOT826; p<0.05), Prevotella 
melaninogenica (p<0.05) and Prevotella salivae (p<0.05), were significantly greater in 
implants than teeth (Figure 11). However, after adjusting for multiple comparisons, there 
were no significant differences in relative abundance of any of the OTUs between 
implants and teeth at this time point.  
 
Figure 11. Relative abundances of OTUs that were statistically significantly different 
between teeth and implants on day -14 prior to adjusting for multiple comparisons. Bars 
represent range of relative abundance values. 
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The second aim of this thesis (Aim 2) was to longitudinally evaluate the changes in the 
microbial flora and GCF inflammatory markers during 21 days of de novo plaque 
accumulation around dental implants in comparison to teeth.  
 
4.3.1 Clinical results 
At baseline (day 0), GI (Figure 4b), PlI (Figure 4c) and ABS (Figure 4d) values were zero 
for both teeth and implants, indicating absence of clinical signs of inflammation. During 
the experimental phase, both teeth and implants accumulated plaque and developed 
clinical signs of inflammation, peaking at day 21 (Figure 4). GCF volume (Figure 4a), GI 
(Figure 4b), PlI (Figure 4c) and ABS (Figure 4d) were significantly higher on day 21 
compared to day 0 for both teeth and implants. However, teeth and implants showed 
differences in terms of plaque accumulation, with implants accumulating less plaque 
during the experiment (Figure 4c). Consistent with this, GI tended to be lower in implants 
than in teeth at all time points during the experimental period, although these differences 
did not reach statistical significance. Interestingly, despite lower GI in implants, GCF 
volume was higher in implants when compared to teeth on day 7 of the experimental 
phase. This trend was also observed on day 14. ABS values did not differ statistically 
between teeth and implants but there was a trend for higher ABS in implants compared to 
teeth during experimental plaque accumulation. 
 
 
4.3.2 GCF inflammatory marker results 
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The decrease in plaque accumulation and clinical inflammation from day -14 to day 0 
corresponded with lower concentrations of several of the inflammatory markers. Only IL-
1 ra (Figure 6c) was significantly lower on day 0 compared to day -14 for both teeth and 
implants. For implants only, the absence of plaque on day 0 resulted in decreased 
lactoferrin (Figure 5a) and GRO (Figure 7) compared to day -14. For teeth only, IL-1 
alpha (Figure 6a) and IL-1 beta (Figure 6b) were significantly reduced on day 0 
compared to day -14.  
 
As plaque accumulation and clinical signs of inflammation increased over the 
experimental phase, many of the inflammatory markers also increased. Members of the 
IL-1 cytokine family seemed to be the most consistent biomarkers for plaque 
accumulation around both implants and teeth (Figure 6). IL-1 alpha (Figure 6a), IL-1 beta 
(Figure 6b) and IL-1 ra (Figure 6c) demonstrated significantly greater concentration at 
day 21 compared to day 0 for both implants and teeth. The PMN activity marker 
lactoferrin (Figure 5a), and to a lesser extent MPO (Figure 5b) and the chemokine IL-8 
(Figure 5c), marked experimental gingivitis but not peri-implant mucositis; whereas 
CCL22 (Figure 5d) was a marker for experimental peri-implant mucositis only. TNF-
alpha (Figure 6d) and GRO (Figure 7) concentrations did not change significantly 
throughout the experimental period for either teeth or implants.  
 
Across group comparisons showed that on day 7, IL-1 ra (Figure 6c) was significantly 
higher at implants compared to teeth. On day 14, TNF-alpha (Figure 6d) was 
significantly higher at implants compared to teeth. On day 21, TNF-alpha (Figure 6d) and 
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CCL22 (Figure 5d) were significantly higher at implants compared to teeth. These results 
are consistent with the trend for implants to display higher levels of inflammatory 
markers than their teeth counterparts. However, there were no significant differences in 
lactoferrin (Figure 5a), MPO (Figure 5b), IL-8 (Figure 5c), IL-1 alpha (Figure 6a), IL-1 
beta (Figure 6b) and GRO (Figure 7) between implants and teeth during the experimental 
phase.  
 
The subject-specific magnitude of change in concentrations of inflammatory markers 
over the experimental phase was also evaluated. Deltas were calculated by subtracting the 
earlier visit value from the later visit value. The deltas from day 0 to 7 for IL-1 alpha, IL-
1 beta and TNF-alpha were significantly greater for teeth compared to implants (p<0.05). 
The delta from day 0 to 14 for MPO was significantly greater for teeth compared to 
implants (p<0.05). These results suggest a greater early response for these biomarkers in 
teeth compared to implants. 
 
In summary, IL-1 alpha, IL-1 beta and IL-1 ra were biomarkers for plaque accumulation 
around both teeth and implants. Lactoferrin was a marker of experimental gingivitis but 
not of peri-implant mucositis while CCL22 was a marker for experimental peri-implant 
mucositis only. 
 
4.3.3 Microbiological results 
As expected from the PlI results, subgingival bacterial load at teeth and implants was 
significantly lower on day 0 compared to day -14 (Figure 8). Subgingival bacterial load 
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increased significantly over the experimental phase, with a dramatic difference between 
day 0 and day 21 for both teeth and implants (Figure 8). None of the measures of alpha 
diversity were different on day 0 compared to day -14 for teeth or implants, however. 
Richness (Figure 9a), evenness (Figure 9b) and non-parametric Shannon Index (Figure 9c) 
increased from day 0 to day 21 for teeth but not implants. The Inverse Simpson Index did 
not differ throughout the experimental phase for teeth or implants. In accordance with the 
PlI results, subgingival bacterial load was significantly greater in teeth than implants on 
day 14 (Figure 8). There was no significant difference in alpha diversity (Figure 9) 
between implants and teeth during the experimental phase.  
 
The magnitude of the change in subgingival bacterial load and alpha diversity over the 
experimental phase were also compared between teeth and implants. The delta from day 
0 to 14 for subgingival bacterial load was significantly greater for teeth compared to 
implants (p<0.05).  
 
PCoA revealed a significant difference in community structure on day 0 compared to day 
7 (p<0.01) and day 0 compared to day 21 (p<0.01) for teeth, such that there was a shift 
along axis 1 as plaque accumulated. A similar trend, but not statistically significant, was 
observed from day 0 to 14. Since axis 1 captured most of the variability during 
experimental plaque accumulation in teeth, we then explored which OTUs correlated 
with PC1. Figures 12-14 show that Veillonella parvula and R. dentocariosa were 
correlated with PC1 from day 0 to 7, R. dentocariosa was correlated with PC1 from day 0 
to 14 and F. nucleatum ss. animalis and R. dentocariosa were correlated with PC1 from 
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day 0 to 21. The shift along axis 1 comparing day 0 to 7 in teeth was positively correlated 
to V. parvula (r=0.76, p<0.01) and negatively correlated with R. dentocariosa (r=-0.78, 
p<0.01), suggesting that V. parvula may drive the shift in community structure during the 
first week of plaque accumulation while R. dentocariosa may drive community structure 
in health. The shift along axis 1 comparing day 0 to 14 in teeth was negatively correlated 
with R. dentocariosa (r=-0.86, p<0.01), indicating that R. dentocariosa may drive 
community structure in health. The shift along axis 1 comparing day 0 to 21 in teeth was 
positively correlated to F. nucleatum ss. animalis (r=0.78, p<0.01) and negatively 
correlated with R. dentocariosa (r=-0.89, p<0.01), suggesting F. nucleatum ss. animalis 
as the main driver of the shift in community structure after three weeks of plaque 
accumulation while, again, R. dentocariosa drives community structure during health. 
OTUs exhibiting a significant correlation with axis 1 in teeth prior to adjusting for 
multiple comparisons are displayed in Tables 8-13. These also point to expected trends, 
with species from the genera Prevotella, Fusobacterium, Selenomonas, Mogibacterium, 
Atopobium, Treponema, among others, positively correlating with the shift during plaque 
accumulation, while species from the genera Actinomyces, Streptococcus, Rothia and 
some beta-Proteobacteria exhibited a negative correlation. In contrast to the changes 
observed in community structure in teeth, which were expected and in accordance to 
previous studies [18,22], there was not a consistent shift in community structure over 
time for implants (Figures 15-17), suggesting that the microbiome response during 
experimental plaque accumulation differs in teeth and implants, with an unpredictable 
variable response in the latter. The Theta YC Index, which measures the distance 
between samples from one time point to another and thus differences in community 
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structure over time, for teeth and implants is displayed in Figure 18. This figure shows 
that the magnitude of the shift during the experimental period was the same for teeth and 
implants but implants did not shift in a predictable and consistent direction.  
 
Figure 12. PCoA plot of community structure (Theta YC) in teeth from day 0 to day 7. 
Gray = day 0; black = day 7. Red arrows indicate OTUs whose relative abundance was 
significantly correlated with axis 1 and therefore drive variability along this axis. 
 51 
 
 
Figure 13. PCoA plot of community structure (Theta YC) in teeth from day 0 to day 14. 
Gray = day 0; black = day 14. Red arrow indicates an OTU whose relative abundance 
was significantly correlated with axis 1, driving variability along this axis. 
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Figure 14. PCoA plot of community structure (Theta YC) in teeth from day 0 to day 21. 
Gray = day 0; black = day 21. Red arrows indicate OTUs whose relative abundance was 
significantly correlated with axis 1 and therefore drive variability along this axis.
 
Figure 15. PCoA plot of community structure (Theta YC) in implants from day 0 to day 
7. Gray = day 0; black = day 7.  
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Figure 16. PCoA plot of community structure (Theta YC) in implants from day 0 to day 
14. Gray = day 0; black = day 14.  
 
Figure 17. PCoA plot of community structure (Theta YC) in implants from day 0 to day 
21. Gray = day 0; black = day 21.  
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Table 8. Positive Spearman’s Rank-Order Correlations between OTUs and axis 1 for 
teeth from day 0 to day 7 prior to adjusting for multiple comparisons. * = p<0.05; ** = 
p<0.01 
OTU r 
Veillonella parvula 0.76** 
Actinomyces sp. (HOT170) 0.69** 
Fusobacterium sp. (Fusobacterium nucleatum ss. animalis HOT420) 0.57** 
Prevotella salivae 0.53** 
Streptococcus sp. (HOT057) 0.51** 
Atopobium rimae 0.47* 
Actinomyces sp. HOT448 0.47* 
Fusobacterium sp. (Fusobacterium nucleatum ss. nucleatum HOT698) 0.47* 
Leptotrichia sp. HOT223 0.46* 
Oribacterium sp. (HOT372) 0.43* 
Selenomonas noxia 0.43* 
Mogibacterium sp. (Mogibacterium diversum HOT593) 0.43* 
Prevotella sp. HOT317 0.42* 
Prevotella oris 0.42* 
Neisseria bacilliformis HOT013 0.41* 
Lachnoanaerobaculum sp. (Eubacterium [XIVa][G-1] saburreum HOT494) 0.40* 
Prevotella denticola 0.39* 
Dialister invisus 0.38* 
Prevotella sp. HOT305 0.38* 
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Table 9. Negative Spearman’s Rank-Order Correlations between OTUs and axis 1 for 
teeth from day 0 to day 7 prior to adjusting for multiple comparisons. * = p<0.05; ** = 
p<0.01 
OTU r 
Rothia dentocariosa -0.78** 
Pseudomonas stutzeri -0.49** 
Acinetobacter baumannii -0.44* 
Delftia acidovorans HOT023 -0.41* 
Halomonas sp. -0.39* 
Pseudoalteromonas sp. -0.32* 
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Table 10. Positive Spearman’s Rank-Order Correlations between OTUs and axis 1 for 
teeth from day 0 to day 14 prior to adjusting for multiple comparisons. * = p<0.05; ** = 
p<0.01 
OTU r 
Veillonella parvula 0.59** 
Prevotella nigrescens 0.58** 
Campylobacter gracilis 0.58** 
Mogibacterium sp. (Mogibacterium diversum HOT593) 0.57** 
Fusobacterium sp. (Fusobacterium nucleatum ss. animalis) 0.52** 
Pseudoramibacter alactolyticus 0.50* 
Anaeroglobus geminatus 0.49* 
Solobacterium moorei 0.48* 
Veillonellaceae [G-1] HOT129 0.48* 
Anaeroglobus geminatus 0.47* 
Atopobium rimae 0.47* 
Neisseria oralis 0.46* 
Oribacterium sp. HOT102 0.46* 
Anaeroglobus geminatus 0.46* 
Atopobium rimae 0.46* 
Shuttleworthia satelles 0.46* 
Parvimonas micra 0.46* 
Prevotella multisaccharivorax 0.46* 
Comamonas testosteroni 0.46* 
Aggregatibacter actinomycetemcomitans 0.46* 
Alloprevotella rava 0.46* 
Aggregatibacter paraphrophilus 0.43* 
Parvimonas micra 0.41* 
Leptotrichia goodfellowii 0.40* 
Veillonella parvula 0.40* 
Fusobacterium sp. (Fusobacterium nucleatum ss. nucleatum) 0.40* 
Dialister invisus 0.40* 
Prevotella denticola 0.39* 
Prevotella oris 0.38* 
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Table 11. Negative Spearman’s Rank-Order Correlations between OTUs and axis 1 for 
teeth from day 0 to day 14 prior to adjusting for multiple comparisons. * = p<0.05; ** = 
p<0.01 
 
 
  
OTU r 
Rothia dentocariosa -0.86** 
Actinomyces sp. (HOT169) -0.52** 
Actinomyces sp. HOT171 -0.48* 
Pseudomonas stutzeri -0.45* 
Actinomyces sp. HOT169 -0.44* 
Acinetobacter baumannii -0.42* 
Streptococcus sp. (HOT068) -0.42* 
Leptotrichia sp. HOT221 -0.41* 
Kingella oralis -0.40* 
Actinomyces sp. (Actinomyces naeslundii HOT176) -0.39* 
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Table 12. Positive Spearman’s Rank-Order Correlations between OTUs and axis 1 for 
teeth from day 0 to day 21 prior to adjusting for multiple comparisons. * = p<0.05; ** = 
p<0.01 
OTU r 
Fusobacterium nucleatum ss. animalis 0.78** 
Mogibacterium sp. (Mogibacterium diversum) 0.65** 
Prevotella oris 0.65** 
Prevotella nigrescens 0.63** 
Prevotella sp. (HOT292) 0.56** 
Selenomonas sp. (Selenomonas flueggei) 0.56** 
Fusobacterium sp. (Fusobacterium nucleatum ss. nucleatum) 0.53** 
Atopobium rimae 0.52** 
Selenomonas sp. HOT126 0.51** 
SR1 [G-1] sp. HOT874 0.50** 
Dialister invisus 0.49* 
Granulicatella elegans 0.48* 
Porphyromonas sp. 0.48* 
Treponema sp. (Treponema socranskii ss.paredis) 0.46* 
Oribacterium sp. (HOT372) 0.46* 
Atopobium rimae 0.46* 
Prevotella sp. HOT309 0.45* 
Eubacterium [XI][G-3] brachy 0.44* 
Campylobacter gracilis 0.44* 
Treponema sp. HOT237 0.43* 
Alloprevotella tannerae 0.43* 
Mitsuokella sp. HOT131 0.43* 
Prevotella denticola 0.42* 
Leptotrichia sp. (HOT392) 0.42* 
Porphyromonas sp. HOT279 0.42* 
Prevotella oris 0.42* 
Aggregatibacter sp. HOT512 0.42* 
Dialister pneumosintes 0.42* 
Selenomonas sputigena 0.41* 
Leptotrichia sp. HOT215 0.41* 
Solobacterium moorei 0.41* 
Treponema sp. (Treponema socranskii ss.socranskii) 0.41* 
Peptococcus sp. (HOT167) 0.40* 
Selenomonas sp. (HOT892) 0.39* 
Alloprevotella rava 0.39* 
Streptococcus mitis bv 2 0.38* 
Prevotella oulorum 0.38* 
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Table 13. Negative Spearman’s Rank-Order Correlations between OTUs and axis 1 for 
teeth from day 0 to day 21 prior to adjusting for multiple comparisons. * = p<0.05; ** = 
p<0.01 
OTU r 
Rothia dentocariosa -0.89** 
Actinomyces sp. (HOT169) -0.57** 
Actinomyces sp. (Actinomyces naeslundii HOT176) -0.50** 
Acinetobacter baumannii -0.49* 
Pseudomonas stutzeri -0.48* 
unclassified Proteobacteria -0.47* 
Streptococcus sp. (HOT068) -0.45* 
Rothia mucilaginosa HOT681 -0.41* 
Pseudoalteromonas sp. -0.39* 
 
 
 
Figure 18. Theta Index for teeth and implants over time. Bars indicate median and range. 
No significant differences were found between groups. 
 
OTUs that exhibited a significant difference in change in relative abundance from day 0 
to day 21 prior to adjusting for multiple comparisons are displayed in Table 14 for teeth 
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and Table 15 for implants. Several of the OTUs that demonstrated significant differences 
in change in relative abundance from day 0 to day 21 were the same between implants 
and teeth, including unclassified Proteobacteria, Pseudoalteromonas sp., Selenomonas sp. 
(S. flueggei), unclassified Bradyrhizobiaceae (Afipia broomeae), Vibrio sp., Aeromonas 
sp., Stenotrophomonas maltophilia, Pseudomonas sp. (P. pseudoalcaligenes), Prevotella 
oris and Capnocytophaga leadbetteri. However, after adjusting for multiple comparisons, 
there were no significant differences in relative abundance of any of the OTUs from day 
0 to day 21 for teeth or implants. 
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Table 14. OTUs that demonstrated significant differences in relative abundance from day 
0 to day 21 in teeth prior to adjusting for multiple comparisons. * = p<0.05; ** = p<0.01 
OTU Δ Relative abundance day 0 to 21 
Fusobacterium sp. (F. nucleatum ss. polymorphum) 0.0392* 
Alloprevotella tannerae 0.0368* 
Prevotella oris  0.0247* 
Prevotella oulorum 0.0188* 
Aggregatibacter sp. (HOT458) 0.0144* 
Selenomonas sputigena 0.0085* 
Leptotrichia wadei 0.0085* 
Porphyromonas sp. (P. catoniae) 0.0066* 
Prevotella sp. (HOT292) 0.0064* 
Selenomonas sp. (S. flueggei) 0.0050* 
Streptococcus sp. HOT071 0.0037* 
Atopobium parvulum 0.0028* 
Moryella sp. (Moryella sp. HOT419) 0.0027* 
Prevotella salivae 0.0018* 
Oribacterium sp. (HOT372) 0.0017* 
Prevotella maculosa 0.0017* 
Megasphaera micronuciformis 0.0015* 
Gemella morbillorum 0.0015* 
Capnocytophaga leadbetteri 0.0008* 
Selenomonas artemidis 0.0006* 
Oribacterium sinus 0.0006* 
Alloprevotella rava 0.0005* 
Porphyromonas sp. (HOT275) 0.0003* 
Lachnoanaerobaculum umeaense 0.0003* 
Bacillaceae 1 sp. -0.0001* 
unclassified Bradyrhizobiaceae (Afipia broomeae) -0.0006* 
Stenotrophomonas maltophilia -0.0006* 
Aeromonas sp. -0.0007* 
Corynebacterium durum -0.0008* 
Pseudomonas sp. (P. pseudoalcaligenes) -0.0014* 
Pseudoalteromonas sp. -0.0021** 
Vibrio sp. -0.0024* 
Streptococcus sp. (HOT064) -0.0052* 
unclassified Proteobacteria -0.0061** 
Rothia dentocariosa -0.2432** 
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Table 15. OTUs that demonstrated significant differences in relative abundance from day 
0 to day 21 in implants prior to adjusting for multiple comparisons. * = p<0.05; ** = 
p<0.01 
OTU Δ Relative abundance day 0 to 21 
Prevotella oris 0.0251* 
Tannerella forsythia 0.0065* 
Selenomonas sp. (S. flueggei) 0.0039* 
Capnocytophaga leadbetteri 0.0034* 
Eikenella corrodens 0.0026* 
Treponema sp. (T. socranskii ss. socranskii) 0.0004* 
Actinomyces sp. HOT181 -0.0003* 
Streptococcus sp. (HOT068) -0.0003* 
Streptococcus sp. (S. australis) -0.0003* 
Delftia acidovorans -0.0004* 
Agrobacterium tumefaciens -0.0004* 
Pseudomonas stutzeri -0.0005* 
Gemella sanguinis -0.0006* 
Actinomyces sp. (A. oris) -0.0007* 
Streptococcus sp. (Streptococcus infantis) -0.0015* 
Aeromonas sp. -0.0018* 
unclassified Bradyrhizobiaceae (Afipia broomeae) -0.0021* 
Actinomyces sp. (HOT170) -0.0028* 
Streptococcus sp. (HOT055) -0.0037* 
Rothia mucilagniosa -0.0044* 
Stenotrophomonas maltophilia -0.0044* 
Kingella oralis -0.0048* 
Pseudomonas sp. (P. pseudoalcaligenes) -0.0061* 
Pseudoalteromonas sp. -0.0067* 
Granulicatella sp. (G.adiacens) -0.0071* 
Vibrio sp. -0.0099* 
unclassified Proteobacteria -0.0276** 
Pasteurellaceae sp. (Terrahaemophilus aromaticivorans) -0.1169* 
 
To evaluate whether the change in OTU relative abundance occurred in the same manner 
in teeth and implants, we compared via paired-sample Wilcoxon Signed-Rank tests the 
changes (deltas) in relative abundance for all OTUs during the experimental phase. OTUs 
that exhibited a significant difference in change in relative abundance between implants 
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and teeth prior to adjusting for multiple comparisons are displayed in Figure 19 for day 0 
to day 7, Figure 20 for day 0 to day 14 and Figure 21 for day 0 to day 21. In several 
instances, the change in relative abundance of a particular OTU was positive for teeth but 
negative for implants and vice versa (e.g., Corynebacterium durum from day 0 to day 7), 
which is in accordance with the inconsistent response to plaque accumulation in implants 
demonstrated in the PCoA plots. By day 21, several OTUs exhibited this behavior, with 
some of the most striking differences being those of Streptococcus mitis bv 2 and 
Streptococcus sp. HOT 071, and the periodontitis-associated OTUs Treponema 
lecythinolyticum, Porphyromonas endodontalis, Tannerella forsythia and Bacteroidales 
sp. HOT 272, which decreased in teeth during experimental plaque accumulation but 
increased in implants. However, after adjusting for multiple comparisons, there were no 
significant differences in the deltas (day 7-day 0; day 14-day 0; day 21-day 0), 
representing change in relative abundance, of any of the OTUs between implants and 
teeth. 
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Figure 19. Change in relative abundance of OTUs that were statistically significantly 
different between teeth and implants from day 0 to day 7 prior to adjusting for multiple 
comparisons. Bars represent mean and standard deviation. 
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Figure 20. Change in relative abundance of OTUs that were statistically significantly 
different between teeth and implants from day 0 to day 14 prior to adjusting for multiple 
comparisons. Bars represent mean and standard deviation. 
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Figure 21. Change in relative abundance of OTUs that were statistically significantly 
different between teeth and implants from day 0 to day 21 prior to adjusting for multiple 
comparisons. Bars represent mean and standard deviation. 
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In summary, there was higher plaque accumulation as evidenced by higher subgingival 
bacterial load in teeth than implants. Diversity increased moderately during experimental 
plaque accumulation in teeth only. A shift in community structure consistent with 
previous studies was observed in teeth. In contrast, implants did not demonstrate an 
increase in diversity and the direction of the shift in microbiome community structure 
surrounding implants was inconsistent among subjects. 
 
4.3 Results related to Aim 3 
The third aim of this thesis (Aim 3) was to compare the immunological and 
microbiological responses after oral hygiene measures are resumed around dental 
implants and teeth.  
 
4.4.1 Clinical results 
Resumed oral hygiene resulted in a significant reduction in PlI from day 21 to day 42 for 
both teeth and implants (Figure 4c) and this corresponded to a statistically significant 
decrease in clinical inflammation, as measured by GI, in both teeth and implants (Figure 
4b). GCF volume (Figure 4a) and ABS (Figure 4d) decreased significantly from day 21 
to 42 in teeth but not in implants. However, there were no significant differences between 
day -14 and day 42 for any of the clinical parameters for both implants and teeth, 
indicating that implants and teeth return to their native state after three weeks of resumed 
oral hygiene. On day 42, ABS was significantly higher at implants than teeth, suggesting 
that clinical inflammation does not decrease as quickly at implants compared to teeth 
once oral hygiene is reinstated (Figure 4d). 
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4.4.2 GCF inflammatory marker results 
IL-1 alpha (Figure 6a), IL-1 beta (Figure 6b) and IL-1 ra (Figure 6b) concentration 
decreased significantly from day 21 to day 42 for both teeth and implants. Lactoferrin 
concentration decreased significantly from day 21 to day 42 in teeth only (Figure 5a) 
while CCL22 concentration decreased significantly from day 21 to day 42 in implants 
only (Figure 5d). These results are consistent with the observations for these mediators as 
markers of gingivitis, peri-implant mucositis or both during the experimental phase. IL-1 
alpha, IL-1 beta and IL-1 ra seem to be consistent markers for experimental gingivitis and 
peri-implant mucositis progression and resolution. Lactoferrin seems a marker for 
experimental gingivitis progression and resolution only, whereas CCL22 marks 
experimental peri-implant mucositis progression and resolution only. With the exception 
of lactoferrin concentration at teeth (Figure 5a), there were no significant differences 
between day -14 and day 42 for the inflammatory markers for both implants and teeth, 
again indicating that implants and teeth return to their native state after three weeks of 
resumed oral hygiene. Moreover, consistent with what was seen at the native state, on 
day 42, implants tended to have greater levels of all inflammatory markers, 
demonstrating statistically significantly higher concentrations of CCL22 (Figure 5d) and 
TNF-alpha (Figure 6d) compared to teeth. 
 
4.4.3 Microbiological results 
Subgingival bacterial load was significantly lower on day 42 than day 21 for both teeth 
and implants (Figure 8). Alpha diversity (Figure 9) was significantly lower on day 42 
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than day 21 for teeth only. Intergroup comparisons showed no differences in subgingival 
bacterial load and alpha diversity between teeth and implants at day 42. To evaluate 
whether the change in OTU relative abundance occurred in the same manner in teeth and 
implants, we compared the changes in relative abundance for all OTUs during resolution. 
OTUs that demonstrated a significant difference in change in relative abundance between 
implants and teeth prior to adjusting for multiple comparisons are displayed in Figure 22. 
The change in relative abundance of R. dentocariosa was greater in teeth than implants. 
The change in relative abundances of Streptococcus sp. HOT071 and Streprococcus sp. 
(S. sanguinis), OTUs associated with health, increased in implants but decreased in teeth. 
After adjusting for multiple comparisons, there were no significant differences in the 
deltas (day 42-day 21), representing change in relative abundance, of any of the OTUs 
between implants and teeth from day 21 to day 42. 
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Figure 22. Change in relative abundance of OTUs that were statistically significantly 
different between teeth and implants from day 21 to day 42 prior to adjusting for multiple 
comparisons. 
 
In summary, both teeth and implants returned to their native state as measured by clinical 
parameters and host inflammatory and microbiological markers. Across group 
comparisons showed that despite a lack of significant difference in PlI (Figure 4c), total 
microbial load (Figure 8) or alpha diversity (Figure 9) between teeth and implants, 
implants had more clinical inflammation, as measured by ABS, and higher concentrations 
of some inflammatory markers than teeth during the resolution phase. This is similar to 
the pre-experimental and experimental phase results.  
 
4.5 Correlations in clinical, host and microbiological markers between teeth and 
implants 
Spearman’s Rank-Order correlations were calculated to determine whether clinical, 
inflammatory and microbiological markers in implants and teeth were correlated at each 
time point as well as at all time points taken together (Table 16). A positive correlation 
indicates that the marker behaved in a subject-dependent manner in implants and teeth, 
while negative correlation indicates that the marker behaved differently in implants 
compared to teeth.  
 71 
 
Table 16. Spearman’s Rank-Order Correlations between test (implants) and control 
(teeth) for each marker at each time point. Significant differences between groups are 
indicated in bold. 
Marker -14 0 7 14 21 42 All 
GCF 0.01 
(NS) 
-0.26 
(NS) 
0.07 
(NS) 
0.08 
(NS) 
0.05 
(NS) 
-0.06 
(NS) 
0.14 
(NS) 
GI 0.64 
(p<0.01) 
 0.37 
(NS) 
0.40 
(NS) 
0.48 
(NS) 
0.15 
(NS) 
0.74 
(p<0.01) 
PlI 0.48 
(NS) 
 0.71 
(p<0.01) 
0.54 
(p<0.05) 
0.41 
(NS) 
0.38 
(NS) 
0.86 
(p<0.01) 
ABS 0.51 
(p<0.05) 
0.17 
(NS) 
0.34 
(NS) 
0.17 
(NS) 
0.47 
(NS) 
0.37 
(NS) 
0.41 
(p<0.01) 
LF 0.39 
(NS) 
0.01 
(NS) 
-0.12 
(NS) 
0.54 
(p<0.05) 
0.25 
(NS) 
0.29 
(NS) 
0.20 
(NS) 
MPO 0.18 
(NS) 
0.14 
(NS) 
0.00 
(NS) 
0.37 
(NS) 
0.06 
(NS) 
0.48 
(NS) 
0.26 
(p<0.05) 
IL-8 0.71 
(p<0.01) 
0.70 
(p<0.01) 
0.49 
(NS) 
0.56 
(p<0.05) 
0.53 
(p<0.05) 
0.89 
(p<0.01) 
0.68 
(p<0.01) 
CCL-22 0.19 
(NS) 
0.00 
(NS) 
0.10 
(NS) 
0.24 
(NS) 
-0.02 
(NS) 
0.60 
(p<0.05) 
0.23 
(p<0.05) 
IL-1 alpha -0.13 
(NS) 
0.23 
(NS) 
0.10 
(NS) 
0.23 
(NS) 
0.16 
(NS) 
0.00 
(NS) 
0.28 
(p<0.01) 
IL-1 beta 0.13 
(NS) 
0.06 
(NS) 
0.25 
(NS) 
0.68 
(p<0.01) 
0.39 
(NS) 
0.27 
(NS) 
0.37 
(p<0.01) 
IL-1 ra 0.08 
(NS) 
0.12 
(NS) 
0.15 
(NS) 
-0.18 
(NS) 
0.01 
(NS) 
-0.16 
(NS) 
0.23 
(p<0.05) 
TNF-alpha 0.32 
(NS) 
0.55 
(p<0.05) 
0.35 
(NS) 
0.41 
(NS) 
0.75 
(p<0.01) 
0.18 
(NS) 
0.46 
(p<0.01) 
GRO -0.31 
(NS) 
0.30 
(NS) 
0.44 
(NS) 
0.60 
(p<0.05) 
0.40 
(NS) 
0.50 
(NS) 
0.45 
(p<0.01) 
Bacterial 
Load 
-0.01 
(NS) 
0.23 
(NS) 
0.65 
(p<0.01) 
0.24 
(NS) 
0.81 
(p<0.01) 
-0.01 
(NS) 
0.46 
(p<0.01) 
Richness 0.14 
(NS) 
-0.39 
(NS) 
0.53 
(NS) 
0.36 
(NS) 
0.41 
(NS) 
-0.03 
(NS) 
0.14 
(NS) 
Evenness 0.43 
(NS) 
-0.07 
(NS) 
0.24 
(NS) 
0.12 
(NS) 
0.37 
(NS) 
-0.06 
(NS) 
0.14 
(NS) 
Shannon 
Index 
0.27 
(NS) 
-0.09 
(NS) 
0.34 
(NS) 
0.23 
(NS) 
0.55 
(p<0.05) 
0.00 
(NS) 
0.14 
(NS) 
Inverse 
Simpson 
Index 
0.29 
(NS) 
-0.04 
(NS) 
0.43 
(NS) 
0.19 
(NS) 
0.36 
(NS) 
0.13 
(NS) 
0.15 
(NS) 
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4.5.1 Native condition 
On day -14, there were several statistically significant between-group correlations. GI 
(r=0.64, p<0.01) and ABS (r=0.51, p<0.05) and IL-8 (r=0.71, p<0.01) concentrations at 
implants and teeth were correlated, which suggests that implants and teeth have similar 
clinical inflammatory and PMN chemokine responses during the native condition (Table 
16). There was also a trend for a positive correlation between PlI at implants and PlI at 
teeth, suggesting that plaque accumulation in the native condition occurs in a subject-
specific manner. Interestingly, GCF volume and several inflammatory markers did not 
show a significant correlation, a result in accordance with differences observed between 
teeth and implants at day -14 (Figures 4-7), with implants showing a trend for higher 
levels than teeth.  
 
4.5.2 Experimental phase 
There were several statistically significant between-group correlations during the 
experimental phase (Table 16). On day 0, IL-8 (r=0.70, p<0.01), TNF-alpha (r=0.55, 
p<0.05) and bacterial load (r=0.55, p<0.05) in teeth and implants were significantly 
positively correlated. There were also significant positive correlations in teeth and 
implants for bacterial load on day 7 (r=0.65, p<0.01) and day 21 (r=0.81, p<0.01), 
suggesting that total 16S rRNA copy number varies in a subject-dependent manner in 
implants and teeth during experimental gingivitis/peri-implant mucositis. Consistent with 
this finding, PlI at teeth and implants was positively correlated on day 7 (r=0.71, p<0.01) 
and also on day 14 (r=0.54, p<0.05). In addition to day 0, IL-8 at teeth was positively 
correlated to IL-8 at implants on day 14 (r=0.56, p<0.05) and day 21 (r=0.53, p<0.05), 
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although IL-8 concentration does not vary greatly during the experimental phase for teeth 
or implants (Figure 5c). Lactoferrin (r=0.54, p<0.05), IL-1 beta (r=0.68, p<0.01) and 
GRO (r=0.60, p<0.05) in teeth and implants were significantly positively correlated on 
day 14. TNF-alpha (r=0.75, p<0.01) and non-parametric Shannon Index (r=0.55, p<0.05) 
in teeth and implants were significantly positively correlated on day 14. Since several 
clinical, inflammatory and microbiological markers in teeth and implants are positively 
correlated to each other during the experimental phase, it seems that teeth and implants 
respond in a subject-specific manner to plaque accumulation. 
 
4.5.3 Resolution 
On day 42, IL-8 (r=0.89, p<0.01) and CCL22 (r=0.60, p<0.05) concentrations at implants 
and teeth were correlated, which suggests that these cytokines respond in a subject-
specific manner in implants and teeth during resolution (Table 16).  
 
4.5.4 Correlations between teeth and implants at all visits 
In order to evaluate if variation of biomarkers in teeth and implants was correlated across 
the trial in a subject-dependent manner, we tested intergroup correlations taking into 
account all time points. This analysis showed that regardless of time point, GI (r=0.74, 
p<0.01), PlI (r=0.86, p<0.01) and ABS (r=0.41, p<0.01), but not GCF, were correlated 
between implants and teeth (Table 16). These results suggest that the changes in these 
parameters during the trial follow a subject-specific pattern despite differences in total 
plaque accumulated by teeth and implants during the experimental phase (Figure 4).  
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With the exception of lactoferrin, the host inflammatory marker concentrations in teeth 
were correlated to those in implants overall (Table 16). This result may be due to the fact 
that, as seen in figure 5a, lactoferrin concentration increased significantly as plaque 
accumulation increased in teeth but it did not increase in implants. 
 
Total 16S rRNA copy number in teeth was correlated to that in implants (r=0.46, p<0.01) 
while alpha diversity in teeth was not correlated to that in implants overall (Table 14). 
Subgingival bacterial load increased similarly in teeth and implants with increased plaque 
(Figure 8). On the other hand, alpha diversity increased as plaque accumulation increased 
in teeth but not in implants (Figure 9). 
   
4.6 Correlations among all variables evaluated 
In order to test which variables (clinical, host and microbiological) better correlated with 
inflammation as determined by GI and ABS and with plaque accumulation as determined 
by PlI and bacterial load, we determined Spearman’s Rank-Order correlations taking all 
six visits together. All clinical and host marker variables were considered for this 
analyses while selected OTUs were tested. OTUs selected for correlations in the teeth 
group were those displaying the highest correlation coefficients with PC1 in PCoA 
analysis plots during experimental plaque accumulation for the three time points tested. 
OTUs selected for correlation analysis in the implant group were those displaying the 
highest correlation coefficients with both PC1 and PC2 at day 21 only, as this was the 
only day with more consistent trends in microbiome shifts in implants. The variables 
were organized into correlograms based on results from hierarchical clustering for teeth 
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(Figure 22) and implants (Figure 23). In teeth, GI was positively correlated with ABS, PlI, 
subgingival bacterial load, MPO, lactoferrin, IL-1 alpha, IL-1 beta, IL-1 ra and the OTUs 
C. gracilis, Selenomonas sp. (S. fluggei), Fusobacterium sp. (F. nucleatum ss. nucleatum) 
and three OTUs in the genera Prevotella and negatively correlated with R. dentocariosa 
(Figure 22). ABS in teeth was positively correlated with GI, PlI IL-1 alpha, IL-1 beta, IL-
1 ra, lactoferrin Fusobacterium sp. (F. nucleatum ss. animalis), Atopobium rimae and two 
OTUs in the genera Prevotella (Figure 22). PlI in teeth in turn was positively correlated 
with MPO, lactoferrin, IL-1 alpha, IL-1 beta, IL-1 ra, measures of alpha diversity, C. 
gracilis, Selenomonas sp. (S. fluggei), Fusobacterium sp. (F. nucleatum ss. nucleatum) 
and OTUs in the genera Prevotella and negatively correlated with R. dentocariosa 
(Figure 22). Lastly, subgingival bacterial load in teeth was positively correlated with C. 
gracilis, Selenomonas sp. (S. fluggei), OTUs in the genera Prevotella, IL-1 ra, IL-1 alpha 
and TNF-alpha and negatively correlated with R. dentocariosa (Figure 22). Since IL-1 
alpha, IL-1 beta, IL-1 ra (Figure 6a-c) and lactoferrin (Figure 5a) were biomarkers of 
experimental plaque accumulation in teeth and Fusobacterium sp. (F. nucleatum ss. 
animalis) was positively correlated with the shift in axis 1 from day 0 to day 21 in teeth 
(Figure 14), these positive correlations were expected. Since R. dentocariosa was 
negatively correlated with the shift in axis 1 from day 0 to day 7 (Figure 12), day 0 to day 
14 (Figure 14) and day 0 to day 21 (Figure 14) in teeth, this negative correlation was 
expected. 
 
In implants, GI was positively correlated with MPO, lactoferrin, IL-1 alpha, IL-1 beta, 
IL-1 ra and OTUs of the genera Treponema and Capnocytophaga sp. (C. gingivalis) and 
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negatively correlated with R. dentocariosa and Streptococcus sp. (S. mitis; Figure 23). 
ABS in implants was positively correlated with GRO, MPO, lactoferrin, IL-1 alpha, IL-1 
beta and IL-1 ra alpha and negatively correlated with Streptococcus sp. (S. mitis; Figure 
23). PlI in implants was positively correlated with IL-1 alpha, IL-1 beta, IL-1 ra and 
Capnocytophaga sp. (C. gingivalis) and negatively correlated with R. dentocariosa. 
Lastly, bacterial load in implant was positively correlated with TNF-alpha, CCL22 and 
Eubacterium [XI][G-1]. Since IL-1 alpha, IL-1 beta, IL-1 ra (Figure 6a-c) and CCL22 
(Figure 5d) were biomarkers of experimental plaque accumulation in implants, these 
positive correlations were expected. 
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Figure 22. Within group Spearman’s Rank-Order Correlations for teeth displayed as a 
correlogram based on hierarchical clustering. Colors indicate correlation coefficients. 
Non-significant correlations (more than 0.05) are marked with an x. Red = positive 
correlation; purple = negative correlation. Samples were organized based on hierarchical 
clustering results showing clusters of samples that correlate with each other. 
 
Figure 23. Within group Spearman’s Rank-Order Correlations for implants displayed as 
a correlogram based on hierarchical clustering. Colors indicate correlation coefficients. 
Non-significant correlations (more than 0.05) are marked with an x. Red = positive 
correlation; purple = negative correlation. Samples were organized based on hierarchical 
clustering results showing clusters of samples that correlate with each other. 
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We also employed Spearman’s Rank-Order Correlation test to examine whether presence 
or absence of crowns on teeth was related to plaque accumulation since we observed 
increased plaque accumulation in teeth in comparison to implants during the 
experimental phase. A within group correlation analysis between presence of crowns and 
PlI showed a significant negative correlation at day -14 and 42 and a trend toward a 
negative correlation between the presence of a crown and increased PlI on day 7 and day 
14, indicating that plaque accumulation tended to be lower in the presence of crowns 
(Table 17). 
 
Table 17. Spearman’s Rank-Order Correlations between presence of crowns and teeth PlI. 
Day -14 and day 42 demonstrated significant negative correlations between presence of 
crowns and PlI. Day 7 and 14 demonstrated a trend toward negative correlations between 
presence of crowns and PlI. 
 Day -14 Day 7 Day 14 Day 21 Day 42 
r -0.58 -0.51 -0.45 -0.32 -0.77 
p-value 0.02 0.05 0.09 0.23 .001 
 
5. Discussion 
This study aimed to compare clinical parameters, GCF inflammatory markers and 
microbial biofilms between teeth and dental implants in their native state as well as to 
evaluate the changes in clinical parameters, inflammatory markers and microbial biofilms 
during 21 days of experimental plaque accumulation and after oral hygiene measures 
were resumed around dental implants in comparison to teeth. The microbiome and host 
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response associated with peri-implant mucositis is not fully understood. The prevention 
and treatment of peri-implant mucositis is critical, as this condition may progress to peri-
implantitis and ultimately loss of the affected implant. Dissimilarities in the microbiomes 
and/or host response associated with peri-implant mucositis versus gingivitis may guide 
different clinical approaches to diagnosis, prevention and therapy. This is the first study 
to characterize the evolution of the whole microbial profile and changes in host response 
at teeth and implant sites during three phases: the native condition, experimental 
gingivitis/peri-implant mucositis and resolution. Although this was a pilot study, subject 
retention was high, with only three of 18 subjects lost. However, sample size was low and 
the data were not normally distributed, which required the use of non-parametric 
statistical tests, and adjustment for multiple comparisons was required as many variables 
were compared. These factors rendered our tests conservative and may have hindered our 
ability to discover true associations. Despite this, we observed several novel results and 
also confirmed results of previous work. Our study may serve as a basis for larger 
experiments of this nature. 
 
During the native state (day -14), GI was significantly higher at teeth compared to 
implants despite equal levels of plaque. In contrast, ABS and GCF volume tended to be 
higher in implants than teeth during the native condition. Implants demonstrated 
significantly higher concentrations of lactoferrin, IL-1 ra and TNF-alpha compared to 
teeth. There was also a trend toward higher concentrations of MPO, CCL-22, IL-1 alpha, 
IL-1 beta, IL-8 and GRO at implants compared to teeth. A trend for lower GI and a 
statistically significant higher ABS in implants compared to teeth were also seen at the 
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resolution phase (day 42). Also in agreement with day -14, higher levels of inflammatory 
markers in implants and teeth were seen at the resolution phase. While all data point to 
greater inflammation in implants in comparison to teeth, GI does not seem to correlate 
well with molecular evidence of inflammation in implants. This may be due to 
differences in histology of implants and teeth. For example, implants lack a PDL and 
therefore the peri-implant mucosa has less vascularity than the gingiva. Since GI is a 
visual assessment based on color, a decreased blood supply will result in less mucosal 
color change. ABS, in contrast, seems to capture inflammation around implants. 
Moreover, reasons for increased inflammation around implants in comparison to teeth 
could not be explained by microbiome analysis, as implants did not have a unique or 
different microbiome than that present on teeth. Subgingival bacterial load was also 
similar between groups. These findings suggest the presence of a higher inflammatory 
response in implants compared to natural teeth despite a similar microbial challenge. In 
agreement with our results, Nowzari et al. (2012) reported significantly higher 
concentrations of pro-inflammatory cytokines IL-8 and TNF-alpha in the peri-implant 
sulcular fluid of healthy implants compared to the GCF of healthy teeth [11]. Differences 
between teeth and dental implants in surface characteristics and chemical composition 
may explain discrepancies in cytokine levels. When a foreign body, even commercially 
pure titanium, is placed in bone or soft tissue, an inflammatory reaction develops. 
Osseointegration of a dental implant is ultimately a foreign body response in the tissues. 
The majority of implants experience a steady state foreign body reaction and maintain 
osseointegration and healthy supporting tissues [61]. However, implants may 
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demonstrate elevated local inflammatory cytokines compared to natural teeth due to this 
foreign body response. 
 
While PCoA revealed that community structure in teeth and implants is the same during 
the native condition, there was a trend for differences in the relative abundances of a few 
OTUs in teeth versus implants. There was a trend for the relative abundances of OTUs A. 
gerencseriae and Capnocytophaga sp. (HOT336) to be greater in teeth compared to 
implants whereas there was a trend for the relative abundances of P. melaninogenica and 
P. salivae to be greater in implants compared to teeth. This is in agreement with Kumar et 
al. (2012), who found higher levels of the genera Actinomyces and Capnocytophaga in 
healthy teeth than healthy implants and higher levels of the genera Prevotella in healthy 
implants than healthy teeth [37]. 
 
During the experimental phase, PlI increased significantly for both implants and teeth, 
demonstrating that the methodology to induce plaque accumulation was effective. 
However, teeth had higher PlI compared to implants over 21 days of oral hygiene 
abstention. Increased plaque accumulation around unrestored teeth compared to ceramo-
metal restorations as a result of differences in surface roughness has been previously 
reported [62]. In our study, there was a trend toward a negative correlation between the 
presence of crowns and PlI in teeth. Accordingly, implants demonstrated less plaque 
accumulation than teeth. Consistent with higher PlI in teeth, GI tended to be higher in 
teeth compared to implants, although this could be due to GI not being an accurate 
marker of inflammation around implants. Salvi et al. (2012), on the other hand, found 
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higher GI at implants compared to teeth despite higher PlI in teeth compared to implants 
during experimental plaque accumulation [38]. Differences in methodology used to 
measure GI between our study and the Salvi et al. (2012) study may explain the disparity 
in these results. We measured GI using the Silness and Loe (1964) [42] method without 
the bleeding component, according to the modification described by Trombelli et al. 
(2004) [43]. Although this method was selected to allow plaque to accumulate in an 
undisturbed manner throughout the experimental phase, the ability to distinguish between 
a GI score of 1 and 2 is limited. This may have resulted in a less sensitive assessment of 
GI. While the mGI method described by Mombelli et al. (1997) [63] used in the Salvi et 
al. (2012) study may have allowed more accurate GI measurement, this technique 
disturbed the biofilm weekly during experimental plaque accumulation. As explained 
before, inflammation around implants may be better measured when there is a bleeding 
component in the scale used, and therefore in this study ABS seemed to better reflect the 
inflammatory status of implants than GI. 
 
As plaque accumulation and clinical signs of inflammation increased over the 
experimental phase, many of the inflammatory markers also increased. IL-1 alpha, IL-1 
beta and IL-1 ra were the most consistent markers for plaque accumulation around both 
teeth and implants. Lactoferrin was a marker of experimental gingivitis but not of peri-
implant mucositis while CCL22 was a marker for experimental peri-implant mucositis 
only. Each of these mediators is characteristic of acute inflammation. IL-1 beta, produced 
primarily by macrophages and PMNs, is a principal mediator of the gingival 
inflammatory response and both IL-1 alpha and IL-1 beta stimulate PGE2 release. 
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Elevated concentrations of IL-1 alpha and IL-1 beta have been associated with both 
naturally occurring and experimental gingivitis [30-33]. In accordance with Salvi et al. 
(2012)[38], IL-1 beta concentration increased as plaque accumulated in both implants and 
teeth. While increased IL-1 ra concentration in periodontitis samples compared to healthy 
samples has been reported, Il-1 ra has not been evaluated in gingivitis or peri-implant 
mucositis. Consistent with previous periodontitis studies [34, 35], the concentration of 
IL-1 ra increased in teeth during the experimental phase in our study. Implants also 
demonstrated an increase in IL-1 ra during experimental peri-implant mucositis. Elevated 
concentration of IL-1ra, the IL-1 receptor antagonist, during experimental plaque 
accumulation may be explained by increased IL-1 ra secretion in response to IL-1 alpha 
and IL-1 beta release in an attempt to dampen the inflammatory response. Since IL-1 ra 
only binds the IL-1 beta receptor and does not affect IL-1 beta production, IL-1 beta 
concentration increased despite increased IL-1 ra concentration during the experimental 
phase. Binding of lipopolysaccharide (LPS) to Toll-like receptor 4 (TLR-4) is essential 
for IL-1 alpha and IL-1 beta secretion in gingival tissue. Increased LPS, due to higher 
proportions of gram-negative organisms as the plaque biofilm matures, stimulates 
secretion of these cytokines [64]. Th17 cells, which require IL-1 for differentiation, 
induce the production of osteoclastogenic mediators RANKL and TNF-alpha [65]. 
Therefore, IL-1 alpha and IL-1 beta, the central mediators in both experimental gingivitis 
and peri-implant mucositis in our study, may be responsible for progression of 
inflammation to an irreversible state (i.e., bone loss).  
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The PMN marker lactoferrin was a biomarker for experimental gingivitis but not peri-
implant mucositis. The observation that lactoferrin concentration increased during 
experimental plaque accumulation around teeth confirms the findings of Ozdemir et al. 
(2009) [66]. Although higher concentrations of lactoferrin in the peri-implant sulcular 
fluid of implants with peri-implantitis compared that of healthy implants have been 
reported [12], lactoferrin was not a reliable marker of peri-implant mucositis in our study. 
Perhaps lactoferrin is a better biomarker for more severe peri-implant lesions.  
 
Produced by macrophages, CCL22 is a chemoattractant for Th2 cells and acted as a 
biomarker for experimental peri-implant mucositis but not gingivitis. Recently, the 
cytokine microenvironment in aseptic loosening of total hip replacements was described 
in the orthopedic literature [67]. Compared to healthy synovial tissues of patients 
undergoing primary hip replacement, interface tissues of failed hip implants 
demonstrated upregulation of CCL22 and presence of foreign body giant cells. Similarly, 
Albrektsson and colleagues introduced the theory that successful osseointegration of 
dental implants relies on foreign body equilibrium [61,68]. This concept suggests that 
marginal bone resorption around dental implants is ultimately the result of a provoked 
foreign body response and is only secondarily related to biofilm-mediated processes. 
Perhaps elevated CCL22 in implants, but not teeth, during experimental plaque 
accumulation indicates a foreign body response to the titanium implant, exacerbated by 
the bacterial biofilm. Finally, the fact that a macrophage-activity marker, but no 
neutrophil marker, was significantly associated with  peri-implant mucositis may indicate 
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that inflammation in the peri-implant mucosa is more of a chronic than acute type 
response. 
 
 Across group comparisons revealed significantly higher IL-1 ra, TNF-alpha and CCL22 
concentrations at implants compared to teeth at various time points during the 
experimental phase. These results are consistent with the trend for implants to display 
higher levels of inflammatory markers than their teeth counterparts. Salvi et al. (2012) 
also found higher MMP-8 concentration at implants compared to teeth during the 
experimental phase, suggesting that implants develop a stronger inflammatory response 
to experimental plaque accumulation than teeth [38]. 
 
The microbiological results from the experimental phase were largely consistent with 
previous work from Löe et al. (1966)[18] and Kistler et al. (2013)[22] that demonstrated 
a shift toward gram-negative, obligate anaerobes over the course of experimental 
gingivitis. In our study, PCoA revealed a significant shift to the right along axis 1 as 
plaque accumulated in teeth. This shift was positively correlated with V. parvula after 
one week and F. nucleatum ss. animalis after three weeks and negatively correlated with 
R. dentocariosa, indicating that V. parvula and F. nucleatum ss. animalis are drivers of 
community structure during experimental plaque accumulation while R. dentocariosa 
drives community structure in health. There was a trend for the relative abundances of 
OTUs Selenomonas sp. (S. flueggei), S. sputigena, S. artemidis, Fusobacterium sp. (F. 
nucleatum ss. polymorphum), Porphyromonas sp. (HOT275), Porphyromonas sp. (P. 
catoniae) and L. wadei to increase from day 0 to day 21 in teeth. This is in agreement 
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with Kistler et al. (2013), who found higher levels of the genera Selenomonas, 
Fusobacterium, Porphyromonas and Leptotrichia during experimental gingivitis [22]. In 
contrast to Kistler et al. (2013), who took plaque samples from the same sites each week, 
we obtained biofilm samples from different sites throughout the study, allowing plaque to 
accumulate in an undisturbed fashion. While this method was advantageous in that it 
allowed the biofilm to mature over time, it also introduced variability, as the microbiome 
could have been different at different sites.  
 
This is the first study to characterize the whole microbiome during experimental peri-
implant mucositis. The magnitude of the shift in community structure over time, as 
measured by Theta Index, was the same for teeth and implants. Moreover, the relative 
abundances of many gram-negative OTUs, such as T. forsythia and Eikenella corrodens, 
tended to increase, while gram-positive organisms, such as R. dentocariosa, tended to 
decrease during experimental peri-implant mucositis, indicating a trend similar to teeth. 
However, the shift in the microbiome structure was less predictable in implants compared 
to teeth as evidenced by the different directions in which the microbiome community 
structure shifted in PCoA analyses. Since the shift in community structure was consistent 
in experimental gingivitis but inconsistent in experimental peri-implant mucositis, the 
microbiome response during experimental plaque accumulation seems to differ between 
teeth and implants. Perhaps surface characteristics determine different biofilm 
development patterns in implants. It is also possible that since plaque did not accumulate 
as much at implants, the peri-implant biofilm may not have had as much time to mature 
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as the biofilm surrounding teeth, which may also explain why diversity increased from 
day 0 to day 21 for teeth but not implants.  
 
During resolution, all clinical parameters returned to their native state values for both 
implants and teeth. However, ABS was significantly higher at implants than teeth on day 
42, indicating that clinical inflammation does not decrease as quickly at implants 
compared to teeth once oral hygiene practices are resumed. Salvi et al. (2012)[38] also 
found greater clinical inflammation, as measured by GI, at implants compared to teeth on 
day 42. Resolution of peri-implant mucositis may require a longer healing period than 
gingivitis. Consistent with the experimental phase observations, IL-1 alpha, IL-1 beta and 
IL-1 ra seem to be consistent markers for experimental gingivitis and peri-implant 
mucositis resolution since the concentrations of these mediators decreased significantly 
from day 21 to day 42 in both teeth and implants. Lactoferrin, which significantly from 
day 21 to day 42 in teeth only, may act as a marker for experimental gingivitis resolution 
only, whereas CCL22, which decreased significantly from day 21 to day 42 in implants 
only, may act as a marker for experimental peri-implant mucositis resolution only. 
Similar to the Salvi et al. (2012) host marker results, which demonstrated reversibility of 
experimental gingivitis and peri-implant mucositis at the biomarker level [38], there were 
no significant differences in inflammatory mediator concentration between the native 
state and resolution for both implants and teeth. Although there were no differences in 
subgingival bacterial load or diversity between implants and teeth on day 42, implants 
tended to have greater levels of all inflammatory markers compared to teeth during 
resolution. This observation is similar to the host marker findings during the native state. 
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The within group correlations demonstrate that the host markers MPO, lactoferrin, IL-1 
alpha, IL-1 beta and IL-1 ra best define gingivitis while IL-1 alpha, IL-1 beta, IL-1 ra, 
CCL22 and TNF-alpha best define peri-implant mucositis. OTUs such as C. gracilis, 
Selenomonas sp. (S. fluggei), Fusobacterium sp. (F. nucleatum ss. nucleatum) and 
Fusobacterium sp. (F. nucleatum ss. animalis) and the genera Prevotella were correlated 
with gingivitis. C. gracilis, Fusobacterium sp. (F. nucleatum ss. nucleatum) and 
Fusobacterium sp. (F. nucleatum ss. animalis) have been previously defined as core 
species present in at least 50% of subjects in both healthy and periodontitis groups [69]. 
In contrast, OTUs including Capnocytophaga sp. (C. gingivalis) and Eubacterium 
[XI][G-1] and the genera Treponema were associated peri-implant mucositis. 
Eubacterium [XI][G-1] and OTUs of the genera Treponema were identified as members 
of the core microbiome in periodontitis [69], suggesting that the microbial profile 
associated with peri-implant mucositis may have pathogenic consequences. 
As expected, R. dentocariosa, a member of the core microbiome in periodontal health, 
was negatively correlated with both gingivitis and peri-implant mucositis. Genera 
correlated with gingivitis, such as Fusobacterium and Selenomonas, and peri-implant 
mucositis, such as Eubacterium and Treponema, in our study predicted gingivitis in the 
study by Huang et al. (2014)[23]. The key host markers for gingivitis and peri-implant 
mucositis described above could be used to develop assays for the presence and severity 
of inflammatory disease around teeth and implants. Similarly, tests related to 
identification of organisms associated with gingivitis or peri-implant mucositis in this 
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pilot study may be useful for clinical diagnosis. However, such cytokine and microbial 
tests would require validation in larger cohort studies.  
 
6. Conclusions 
From the work reported herein, it can be concluded that: 
• In the native condition, dental implants have higher concentrations of host 
inflammatory mediators than their teeth counterparts despite equal level of 
bacterial plaque and similar microbiome structure. 
• IL-1 alpha, IL-1 beta and IL-ra are consistent biomarkers of both experimental 
gingivitis and peri-implant mucositis, which suggests that both lesions may 
advance in a similar manner. Lactoferrin, however, is a biomarker for 
experimental gingivitis but not peri-implant mucositis while CCL22 is a 
biomarker for experimental peri-implant mucositis but not gingivitis. 
• During experimental plaque accumulation, the structure of the microbiome 
surrounding teeth evolves in a consistent and predictable direction. On the other 
hand, the shift in microbiome community structure during experimental plaque 
accumulation was less predictable for implants. Teeth accumulate more plaque 
than implants and also demonstrate an increase in diversity of the biofilm as 
plaque accumulates whereas implants do not show changes in diversity. 
• The main drivers of shifts in microbiome structure are V. parvula, Fusobacterium 
sp. (F. nucleatum ss. animalis) and R. dentocariosa around teeth and R. 
dentocariosa and OTUs of the genera Actinomyces around implants. 
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• After 21 days of oral hygiene reinstitution, the gingiva and peri-implant mucosa 
return to their native clinical condition. However, implants have higher ABS 
compared to teeth during resolution. Implants may require longer healing periods 
than teeth after experimental plaque accumulation. 
• Similar to the native state, implants demonstrate higher levels of inflammatory 
mediators than teeth during resolution. 
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